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Abstract 
Modeling a chronic disease like COPD is useful to extrapolate treatment effects observed in 
short-term randomized trials to the medium or long term. A model is also a tool to synthesize 
knowledge from various different sources of information in a consistent way.  
The previous IMTA/RIVM COPD severity stage model relates COPD incidence to age, 
gender and smoking status and COPD progression to age, gender, FEV1% pred at model-
start and smoking status. The current project extended this model by adding exacerbations 
and making it stochastic through the specification of probability distributions around all 
important model parameters. The structure was adjusted to allow for moderate and severe 
exacerbations and the following additional input parameters: frequency of exacerbations by 
COPD severity, case-fatality due to a severe exacerbation, additional decline in lung function 
because of an exacerbation, loss of quality of life and increased costs during an 
exacerbation. These parameters were estimated by quantitative meta-analyses. In addition, 
many of the input long term costs and effects were projected for a variety of COPD 
interventions to illustrate the potential use of the model in cost-effectiveness analysis. 
The number of COPD patients above 45 years of age in 2007, the starting year of the 
simulation, was 320,000, 46% females and 30% current smokers.  
Compared to the reference scenario which represented minimal treatment, the cost-
effectiveness of ten year maintenance treatment with a combination of a long-acting 
bronchodilator (LABA) with an inhaled corticosteroid (ICS) or a LABA alone for all moderate 
and severe COPD patients was estimated to be €10,100 and €7,100 per QALY gained, 
respectively. The cost per QALY of a stop-smoking program consisting of intensive 
counseling plus pharmacotherapy which was provided to all smoking COPD patients during 
one-year was €6,100, when the analysis used a time horizon of twenty years. Two year 
implementation of an interdisciplinary pulmonary rehabilitation program for all patients with 
moderate and severe COPD resulted in an estimate of €12,200 per QALY gained based on a 
five year time horizon. The probability of the interventions to be cost-effective at a ceiling ratio 
of €20,000 was 100% for the combination ICS/LABA, 100% for LABA alone, 98% for the 
smoking cessation intervention and 76% for the pulmonary rehabilitation program.  
The new model can be used to assess the costs and health effects of interventions that aim 
to reduce disease progression, the frequency and or severity of exacerbations and mortality, 
to improve quality of life or combinations of these effects. Interventions that affect other 
outcomes cannot be evaluated. Projections for the intervention scenarios are compared to 
projections for the reference case, representing minimal intervention, to estimate the gain in 
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life expectancy, the gain in QALYs, the number of exacerbations avoided, the difference in 
intervention costs and the savings in COPD-related health care cots. The new model 
presents the uncertainty around the outcomes using probabilistic sensitivity analysis, which is 
the current state of the art for cost effectiveness analyses of interventions.  
The extended COPD model now is a tool allowing policy makers to get an overview of short 
term and long term costs and effects of interventions over the entire chain, from primary 
prevention to care for very severe COPD. Furthermore, being stochastic, the model enables 
to estimate the added value of doing additional research for specific model-parameters in a 
value of information analysis. 
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1. Introduction 
In 2005 we have published a decision analytic cost-effectiveness model of Chronic 
Obstructive Pulmonary Disease (COPD) which was used for two distinct purposes [1]. One 
purpose was to simulate the future burden and costs of COPD in the Netherlands [2] and the 
other purpose was to calculate the cost-effectiveness of interventions to prevent and treat 
COPD [2]. The importance of models such as the COPD model is increasingly recognized 
because they not only provide decision makers with insight in the future health care needs 
but they also provide them with information on the returns of their investments in terms of 
health benefits [3]. Hence, these models can raise the awareness about the future burden of 
COPD, support capacity planning decisions and help policy makers to prioritize the 
investment of scarce resources. 
 
The 2005 COPD model [1] is a multistate transition model that calculates the incidence, 
prevalence, mortality, progression, and health care costs of COPD per GOLD severity stage 
[4]. The COPD model is based on the life table method. It starts from the age-, gender- and 
smoking-class distribution in the general population and models the annual incidence of 
COPD depending on this distribution. The dynamics of the Dutch general population are 
taken into account using prognosis of birth and mortality and estimates of the start, stop, and 
restart rates of smoking. The life table method means that the model follows birth cohorts 
over time. Each year a new birth cohort is added, while the existing cohorts age with one 
year. The model is a multistate model, which, for COPD, implies that we distinguish between 
the following states: no COPD, mild, moderate, severe and very severe COPD and death. 
The model follows COPD patients over their course of disease, from incidence until death. 
Incidence depends on age, gender and smoking status. Disease progression is modelled as 
annual decline in FEV1% predicted, depending on age, gender, smoking status and FEV1% 
predicted. COPD mortality rates depend on age, gender, FEV1% predicted, and smoking 
status. Competing risks have been accounted for by including smoking-related causes of 
death as well as other unrelated causes of death in the model.  
 
The 2005 version of the COPD model had two important shortcomings. It did not include 
exacerbations and all parameters were fixed. With respect to the first shortcoming, the model 
could only assess the impact of interventions that affected the decline in lung function and/or 
the survival. An example of such an intervention is smoking cessation support. However, 
many COPD interventions, such as most medications, exercise training, education, 
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multidisciplinary rehabilitation, and self-management, have not (yet) been shown to influence 
COPD progression. These interventions rather reduce the frequency, severity and/or duration 
of COPD exacerbations, improve exercise capacity, symptoms and/or quality of life. With 
respect to the second shortcoming, a deterministic model only gives point estimates of the 
burden and costs of COPD and the cost-effectiveness of interventions without information 
about the uncertainty of these estimates. This uncertainty results from the model input 
parameters being obtained from sampled data. 
 
The current project aimed at improving the Dutch COPD model and addressing these two 
major shortcomings by including the exacerbations and making the model stochastic. Adding 
exacerbations is important because they are common and contribute to poor health-related 
quality of life [5-7] and high costs [8-10]. Moreover, there is some evidence that frequent 
exacerbations accelerate the progression of the disease [11,12][13]. The frequency of these 
exacerbations increases with the severity of COPD [14,15]. In patients with mild to moderate 
COPD an exacerbation often requires medical attention by a general practitioner or specialist. 
When the severity of COPD increases, exacerbations may become major life events that 
require hospital admission. Hospital mortality of patients admitted for an exacerbation of 
COPD is high and the long-term outcome is poor [4]. Hence, these severe exacerbations 
represent a significant burden on patients as well as on the healthcare system. This makes it 
very important to include them in the model. Taking account of the uncertainty in the input 
parameters by making the model stochastic is also important because it enables us to 
demonstrate the likelihood of certain outcomes to occur and the likelihood of interventions 
being cost-effective. Crucial model parameters were no longer entered as point estimates but 
as distributions from which values were randomly drawn. The uncertainty was then quantified 
using Monte Carlo simulation, where the model is run a large number of times, and iterations 
involve random draws from the distributions of the input parameters. Each iteration results in 
an estimate of the outcomes (e.g. prevalence, costs, and health outcomes) and the mean and 
95% uncertainty interval across these iterations represent the expected outcome values and 
the uncertainty intervals. This process is referred to as a probabilistic sensitivity analysis, and 
is currently regarded as the state of the art in cost-effectiveness analysis [16].  
 
The revised version of the COPD model can be used to evaluate a series of interventions for 
COPD that can be applied during various stages of the disease progression. In the current 
project this was illustrated by estimating the cost-effectiveness of interventions that either 
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reduce the decline in lung function, reduce the exacerbation rate, improve the quality of life, 
reduce mortality or combinations of these effects. More specifically, the model was used to 
address how the cost-effectiveness of two pharmaceutical interventions (i.e. a fixed 
combination of a long-acting bronchodilator with an inhaled corticosteroid or a long-acting 
bronchodilator alone) compares with the cost-effectiveness of a smoking cessation 
intervention (i.e. intensive counselling plus pharmaceutical support) and the cost-
effectiveness of pulmonary rehabilitation? 
 
To summarize, this project aimed to: 
1. revise the 2005 COPD model by building exacerbations into the model 
2. making the model stochastic in order to allow calculating uncertainty  
3. to illustrate the potential of the model by calculating the cost-effectiveness of a 
number of different COPD interventions.  
 
In chapter two a description of the revised model will be given along with a description of how 
the new model input parameters were obtained and existing model parameters were updated. 
Chapter three describes the scenario analyses that were done and chapter four describes the 
one-way sensitivity analysis and the probabilistic sensitivity analyses. In chapter five the 
results of the cost-effectiveness analyses will be presented, including cost-effectiveness 
planes and cost-effectiveness acceptability curves. The analyses were done to illustrate the 
potential use of the model. Chapter six contains the discussion and chapter seven the 
conclusions.  
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2. Model and input data for the reference scenario 
 
2.1 General description of the COPD model 
Figure 1 shows the revised version of the Markov model. The length of a Markov cycle is one 
year and the future projections start in the year 2007. The time horizon of the projections can 
vary between one year and lifetime. 
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Figure 2.1. Description of the Dutch COPD population model 
 
 
Starting point of the model simulation is a description of the Dutch general population in terms 
of age, gender (Table A.1) and smoking status (smokers, former-smokers and never-
smokers) (Table A.2) and the incidence and prevalence of COPD by gender and one-year 
age classes starting at age 45 and ending with age 100 (Table A.3).  
 
The prevalence of COPD in each age and gender class is distributed over the three smoking 
classes using the number of smokers in each smoking class and the relative risks of smokers 
and former smokers to have COPD [17,18] (Table A.4). It assumed that the RR of smokers 
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and former smokers to get COPD is equal to the relative risk to have COPD, which is 
assumed to be equal to the RR to die of COPD. The prevalence of COPD in each age, 
gender and smoking class is further distributed over the four GOLD stages of COPD severity 
using the frequency distribution of FEV1% predicted over all COPD classes that was obtained 
from Dutch GP data [19]. Based on a normal distribution with a mean FEV1% predicted of 
68.3% (SD 19.9%) we estimated that 28% has mild COPD, 54% has moderate COPD, 15% 
has severe COPD and 3% has very severe COPD. The distribution of the FEV1% predicted 
within each COPD severity stage is modelled as a linear function that is obtained from the 
continuous normal distribution (Appendix D). 
 
Like the prevalence, the incidence of COPD in each age and gender class is distributed over 
the three smoking classes using the number of smokers in each smoking class and the 
relative risks of smokers and former smokers to have COPD. The frequency distribution of 
the FEV1% predicted among the incident cases was estimated by the model and defined as 
the distribution that, given disease progression and mortality, would not change the FEV1% 
pred among the prevalent cases in the first year of the model. Based on this normal 
distribution with a mean FEV1% predicted of 76.4% (SD 15.6%) it was estimated that 41% of 
the newly diagnosed COPD patients has mild COPD, 55% has moderate COPD, 4% has 
severe COPD and 0.2% has very severe COPD. 
 
Each year transitions between smoking stages occur. Non-smoking patients can start 
smoking, smoking patients can stop smoking and former smoking patients have a certain 
probability to restart smoking (Table A5). 
 
Once having COPD, there is a probability to progress to the next level of COPD severity. This 
disease progression is modelled as the annual decline in FEV1% predicted, depending on 
gender, age, smoking status and FEV1% predicted (Table A.6). Each exacerbation 
accelerates this decline.  
 
Each stage of COPD is associated with an annual exacerbation rate, which increases as the 
severity of COPD increases. Using an event-based definition of exacerbation-severity, a 
distinction is made between the rate of moderate exacerbations and the rate of severe 
exacerbations, where a severe exacerbation is defined as an exacerbation leading to hospital 
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admission and a moderate exacerbation as an exacerbation leading to a prescription of 
systemic corticosteroids and/or antibiotics. 
Each COPD stage is associated with costs of maintenance therapy and utility values (i.e. 
generic quality of life values). Costs of maintenance therapy increase with age and COPD 
severity and are higher for females than males (Table A.7). Utility values decrease as COPD 
severity increases (Table A.8). 
 
Each exacerbation is associated with costs and a utility decrement. The costs and the 
reduction in utility value are higher for severe exacerbations than for moderate exacerbations. 
The utility decrement is modelled as a proportional reduction from the utility value of the 
COPD stage. 
 
The all-cause mortality consists of the mortality attributable to COPD and the mortality from 
other causes (Table A.9). The latter depends on age, gender and smoking status. The COPD 
attributable mortality depends on age, gender and FEV1% predicted, but not on smoking 
because the impact of smoking on mortality due to COPD is already captured by the 
increased incidence and prevalence of COPD among smokers and former smokers. The 
mortality attributable to COPD is further divided into the mortality that is due to severe COPD 
exacerbations and the remaining COPD attributable mortality.  
 
 
To adapt the 2005 COPD model to the new version shown in figure 1, the following new input 
parameters were estimated: 
- rate of moderate and severe COPD exacerbations by GOLD stage of COPD severity 
(section 2.2) 
- case-fatality rate of a severe COPD exacerbation (section 2.3) 
- decline in FEV1% predicted due to an exacerbation (section 2.4) 
- utility decrement due to a moderate and a severe exacerbation (section 2.5) 
- costs of a moderate and a severe exacerbation (section 2.6). 
 
How these estimates were obtained is described in the next sections. A description of the 
existing input parameters that were updated to more recent values is given in section 2.7.  
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2.2. Exacerbation frequency by GOLD stage 
We aimed to quantify the relation between lung function expressed as FEV1% predicted and 
the annual exacerbation frequency in patients with COPD to be able to calculate the 
exacerbation rates per GOLD stage. First we performed a systematic literature review for 
randomized controlled trials and cohort studies reporting the exacerbation frequency in 
patients receiving care as usual or placebo. Details of the search strategy and the selection 
criteria can be found in a separate paper, added to this report as appendix B. Annual 
frequencies were obtained for the following two outcomes: total exacerbations defined by an 
increased use of health care (event-based) and severe exacerbations defined by a 
hospitalization. The literature search resulted in 19 reports of the total exacerbation frequency 
using an event-based definition and 14 reports of the frequency of severe exacerbations 
defined by a hospitalization. The association between the mean FEV1% predicted of study 
populations in the selected studies and the annual exacerbation frequencies was estimated 
using weighted log linear regression with random effects. The resulting regression equations 
for total exacerbations using an event-based definition and severe exacerbations as reported 
below were built into the model.  
 
Annual total exacerbation rate (event-based definition): 
Rate=0.893*exp[1.181-0.014*FEV1%predicted]  
- 0.893 (se=0.093) 
- 1.181 (se=0.351) 
- -0.014 (se=0.007)  
- Covariance between intercept 1.181 and coefficient -0.014 = -0.00227 
 
Annual severe exacerbation rate: 
Rate=1.072*exp[-1.043-0.013* FEV1%predicted] 
- 1.072 (se=0.154) 
- -1.043 (se=0.904) 
- -0.013 (se=0.020) 
- Covariance between intercept -1.043 and coefficient -0.013 = -0.00176 
 
Each year the mean exacerbation rate per GOLD severity stage was calculated by applying 
the mean FEV1% predicted for each GOLD stage at that time into the estimated equations. In 
 15 
the table below (Table 2.1) the mean exacerbation rates per GOLD stage for the starting year 
of the simulation are shown.  
 
Table 2.1: Estimated annual exacerbation frequency per GOLD stage based on the 
regression equations for the starting year of the simulation 
GOLD stage Mean FEV1% 
predicted at 
start 
Total exacerbations: 
event-based 
definition 
Severe 
exacerbations 
I, Mild COPD  90 0.82 (0.46-1.49) 0.11 (0.02-0.56) 
II, Moderate COPD  65 1.17 (0.93-1.50) 0.16 (0.07-0.33) 
III, Severe COPD  42 1.61 (1.51-1.74) 0.22 (0.20-0.23) 
IV, Very severe COPD  23 2.10 (1.51-2.94) 0.28 (0.14-0.63) 
 
As a result of changes in the mean FEV1%predicted per GOLD stage over time the mean 
exacerbation rate per stage did change.  
 
 
2.3 Case fatality 
The methods and results of the estimation of the case fatality of a severe COPD exacerbation 
have been reported in detail in a separate manuscript (see Appendix C). A short summary is 
given below. We assumed mortality to be increased after a severe exacerbation for COPD 
defined as a hospitalization for COPD. We performed a literature search for studies reporting 
at least 1.5 year survival after a severe exacerbation resulting in hospitalization. For each 
study, we extracted the presented or estimated survival curve and distinguished between the 
critical and the stable period after hospital admission with the survival curve during the stable 
period being flatter than the one during the critical period. Mortality during the stable period 
was then estimated by extrapolating the survival curve during the stable period back to the 
time of exacerbation onset (see Figure 2.2). The case fatality was defined as the additional 
mortality that results from an exacerbation and was calculated as 1 minus the (backwardly) 
extrapolated survival during the stable period at the time of exacerbation onset. Based on six 
studies that fulfilled the inclusion criteria the weighted average case-fatality rate was 
estimated to be 15.6% (95% CI: 10-9%-20.3%). 
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Figure 2.2: Survival curve after hospitalization for an exacerbation of COPD. The dotted line 
represents the extrapolated curve during the stable phase (Schematic figure not based on 
real data). 
 
As age is a significant predictor of mortality [20], we also investigated the association 
between age and mortality after a severe exacerbation in the six studies selected for the 
calculation of the case fatality. On average the probability to die after a hospitalization for an 
exacerbation increased with 4.1% per year increase in age (RR=1.041 95%CI: 1.037-1.045). 
With the use of this relative risk we made the case fatality of a COPD exacerbation in the 
model dependent on age. We applied the mean case fatality of 15.6% to the mean age of the 
COPD population in the papers selected from the literature, i.e. 69 years. For each year 
below 69 years, the case fatality decreased with 4.1%, for each year above 69 years, it 
increased with 4.1%.   
 
 
2.4 Exacerbations and lung function decline 
To estimate the relation between exacerbations and lung function decline we performed a 
search in Medline to find papers published after 1990 reporting this association. We used the 
following search query: 
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COPD or “chronic obstructive pulmonary disease” or “chronic bronchitis” in the title  
AND 
FEV* or lung function in the title 
AND 
Decline or progression in the title 
AND 
Exacerbat* or inflammation* or virus* or illness* in the title or abstract 
 
This search resulted in eleven studies of which five reported the relation between 
exacerbations and decline in lung function. Results are shown in table 2.2.  
 
The largest study, the study of Kanner et al did not provide information about the uncertainty 
around their estimate [11]. If the standard error around the estimate obtained from Kanner 
was assumed to be 0.05, which seems reasonable given the standard errors of the other, 
though smaller, studies, the final weighted average decline per exacerbation was estimated 
to be 0.19% predicted (SE of 0.03). However, due to the large number of assumptions we 
needed to make in the calculations we used an SE of 0.05 in the model.   
Due to the low number of studies, the weighted average decline per exacerbation could not 
be specified for subgroups, such as COPD disease severity.  
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2.5 Exacerbations and quality of life  
We did not change the utility values for the different COPD severity stages. These were kept 
the same as in the publication of the former version of the model[1], which were based on 
EQ-5D and obtained from the study of Borg et al.[24] 
 
Table 2.3: Mean utility scores by COPD severity stage according to GOLD 
GOLD stage: Mean utility score 
(SD) 
Mild COPD 0.8971 (0.1117) 
Moderate COPD 0.7551 (0.2747) 
Severe COPD 0.7481 (0.2991) 
Very severe COPD 0.5493 (0.3129) 
 
To estimate the impact of exacerbations on the number of quality-adjusted life years 
(QALYs), data about the relation between exacerbations and utility values, as measured by 
generic quality of life instruments, such as the EQ-5D were needed. Therefore we performed 
a literature search in Medline for studies published after 1990 using the following search 
query: 
 
COPD or “chronic obstructive pulmonary disease” or “chronic bronchitis” in the title  
AND 
Exacerbation* in the title 
AND 
“Health status” or “quality of life” in the title/abstract 
AND 
Utility or EQ-5D in the title/abstract 
 
The search resulted in four studies of which two reported the relation between exacerbations 
and quality of life using the EuroQol (EQ-5D), one for severe exacerbations[10] and one for 
moderate exacerbations[25]. 
 
Severe exacerbations 
The study of O’Reilly et al [10] provided data on the utility scores during a hospitalization for 
an exacerbation valued with the UK tariff [26]. The EQ-5D was measured both at admission 
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and at discharge. The mean length of hospitalization was 11 days. We assumed the utility 
scores after a severe exacerbation to be reduced for a period equal to the period in which the 
mortality due to a severe exacerbation was increased, about 4.5 months. We further 
assumed that the utility score of a patient admitted with a severe COPD exacerbation had 
returned back to the baseline level 4.5 months after admission. Because the baseline utility 
before the hospitalization was unknown the mean EQ-5D utility of the patients in the study of 
O’Reilly at baseline was approximated using the severity distribution of the patients in the 
study and the utility scores per COPD severity stage from the study of Borg et al [24]. Based 
on the mean utility scores at admission (-0.077 se 0.027), at discharge (0.576 se 0.021) and 
at baseline (0.689 se 0.028), the utility loss due to a severe exacerbation was calculated as 
the area above the curve in figure 2.3 (grey area in the Figure) 
 
Figure 2.3: Mean utility scores after hospitalization for a severe COPD exacerbation over time 
 
To obtain uncertainty around this estimate, the above mentioned calculation was applied to 
2500 random draws from the normal distributions of the utility scores at the three different 
time points. This resulted in 2500 estimates of utility loss due to a severe exacerbation. The 
presented figure is the SE of these 2500 estimates. The mean annual utility loss due to a 
severe exacerbation was estimated to be 0.0332 (se 0.007). Expressed as percentage of the 
mean baseline utility value, 0.689, the annual utility loss due to a severe exacerbation was 
estimated to be 4.82% (se 0.87) of the baseline value. 
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 Moderate exacerbations 
The second study found in our literature search, the study of Patterson et al, reported about 
the utility scores during a moderate exacerbation. In this study patients with chronic bronchitis 
visiting their GP for an acute exacerbation, defined as an increase in symptoms, were 
included. The EQ-5D was measured at the first visit and at a follow-up visit one week after 
completing treatment. Because it was unclear what the time between the two measurements 
was and whether the first measurement was at the start of the exacerbation and the last 
measurement was after the exacerbation, this study was less suitable for our purpose [25]. 
We also had access to a submitted paper by Goossens et al [27], who measured utility 
scores during a moderate exacerbation at four different time points over a period of six 
weeks: i.e. within 48 hours after onset of the exacerbation and 7, 14 and 42 days thereafter. 
In this study which included 59 patients a moderate exacerbation was defined as the 
prescription of antibiotics or systemic steroids but no hospital admission. Utility scores were 
based on the EQ-5D and valued using the UK tariff. The number of QALYs lost due to a 
moderate exacerbation was estimated to be 0.013 (SE 0.0017). Expressed as percentage of 
the mean baseline utility value, 0.783, the annual utility loss due to a moderate exacerbation 
was estimated to be 1.66% (SE 0.22) of the baseline value.  
 
The calculated mean annual utility loss due to a severe and a moderate exacerbation as 
percentage of the baseline utility value, 4.82% and 1.66%, respectively were used in the 
model. We applied these percentages to the baseline utilities of the different COPD severity 
stages. As a result the absolute disutility for respectively a moderate or a severe exacerbation 
varied over the severity stages (see table 2.4).  
 
Table 2.4: Absolute disutilities for a moderate and severe exacerbation according to GOLD 
GOLD stage: Absolute disutility moderate 
exacerbation 
Absolute disutility severe 
exacerbation 
Mild COPD 0.0149 0.0432 
Moderate COPD 0.0125 0.0364 
Severe COPD 0.0124 0.0360 
Very severe COPD 0.0091 0.0265 
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2.6 Exacerbations and costs 
Total direct medical costs for COPD in the Netherlands for the year 2000 specified by age 
and gender were obtained from a previous cost of illness study [28]. Based on a prevalence 
estimate of 305,000 patients in 2000, the total costs for COPD in 2000 were estimated to 
279.7 million euro. These costs were updated to the year 2007 using consumer price indices 
[29]. For the current study the total direct medical costs needed to be divided in exacerbation-
related costs and maintenance costs.  
To calculate the total exacerbation-related costs the cost per moderate and severe 
exacerbation was calculated using resource use and unit costs for a moderate and severe 
exacerbation from Oostenbrink et al [8]. Because that study used different definitions of 
exacerbations we slightly modified the costs estimate of a moderate exacerbation as follows: 
we used mean resource use as observed during a non-severe exacerbation in the paper of 
Oostenbrink, after deleting the inpatient hospital costs. Resource use as observed during a 
severe exacerbation was kept unchanged and assumed to reflect the healthcare use during a 
severe exacerbation defined as a hospitalization. The final costs estimates were updated to 
the year 2007. This resulted in a cost estimate of 94 euro (se 6) for a moderate exacerbation 
and 4100 euro (se 894) for a severe exacerbation.   
Total exacerbation-related costs were calculated as the sum of the costs of moderate and 
severe exacerbations in all four severity stage and calculated as follows: Σ mild-very severe 
number of patients per GOLD severity stage * (moderate exacerbation rate * costs moderate 
exacerbation + severe exacerbation rate * costs severe exacerbation).  
COPD-related maintenance costs were calculated as the total direct medical cost per gender 
and age class minus the exacerbation-related costs per gender and age class. The 
maintenance costs within each gender and age class were divided over the four COPD 
severity stages using ratios for the total COPD costs of a patient with moderate (1.24), severe 
(1.39) or very severe COPD (2.06) compared to the costs of a patient with mild COPD (1.0). 
The ratio for costs of a moderate patient compared to costs of a mild patient were obtained 
from a study of Steuten et al [30]. Ratios of the costs for a severe patient and a very severe 
patient compared to a moderate patient were obtained from Oostenbrink et al [31]. As no data 
about uncertainty around the maintenance costs were available, we assumed a standard 
error of 15% of the mean cost per patient in each subclass.  
Main input parameters used in the model were the gender, age and severity stage-specific 
maintenance costs per patient (see Appendix A7 and the costs for a moderate and severe 
exacerbation, 94 (se 6) and 4100 (se 894) respectively. 
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2.7 Other parameters that were updated 
The incidence, prevalence and mortality input data in our COPD model are linked to the 
RIVM Chronic Disease Model (CDM). These input data have been updated in 2009, adding 
estimates of standard errors. The new version of the CDM was published in VTV2010 [32], 
and includes a description of data sources used. The new values of the most relevant input 
data for our COPD model, demography, smoking prevalence, smoking transition rates and 
relative risks for smokers and former smokers to develop COPD are presented in appendix A. 
Demography data for the year 2007 were obtained from Statistics Netherlands [29]. Updated 
information on smoking prevalence and smoking transition rates were obtained from 
STIVORO [33,34]  Relative risks for smokers and former smokers to get COPD were based 
on the same data source as the 2005 model [17,18]. Appendix A also shows the new 
incidence, prevalence and attributable mortality for COPD adapted from VTV-2010 [32]. 
Prevalence and incidence data in VTV 2010 are based on five general practice data bases, 
Continue Morbiditeits Registratie (CMR) Nijmegen, Landelijk Informatie Netwerk 
Huisartsenzorg (LINH), Registratienet Huisartsenpraktijken (RNH), Registratie Netwerk 
Universitaire Huisartspraktijken Leiden en omstreken (RNUH-LEO) and Transitieproject. For 
the Chronic Disease Model and therefore also for our COPD model, the prevalence and 
incidence estimates used are based on three data bases (CMR, RNH, RNUH-LEO), because 
RNH and Transitieproject were suspected to overestimate COPD incidence. The data on 
COPD related mortality are the data used in the DYNAMO-HIA project, which are originally 
based on the General Practice Research Database (GPRD) from the UK (www.gprd.com). 
More details about the new method used to calculate COPD-related mortality can be found in 
Appendix D.  
Uncertainty around the estimates of COPD incidence, prevalence and mortality was 
estimated using the approach that was used for the RIVM Chronic Disease Model [32]., and 
based on the observed variation between the different GP registries as well as the uncertainty 
within these registries. We varied the three disease parameters jointly to account for the 
association between them.  
First, for incidence and prevalence, random effects models with polynomials of age as an 
explanatory variable were simultaneously estimated. We constructed uncertainty intervals by 
taking random draws from the joint distribution of the model parameters. Likewise a model 
with polynomials of age was estimated for the estimates of the COPD-related mortality. We 
again constructed uncertainty intervals by taking random draws from the joint parameter 
distribution. For the PSA, for each model run a random draw of the joint parameter 
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distribution of COPD incidence and prevalence was taken, that was used to calculate the 
age-dependent incidence rate and prevalence probability. Likewise, a random draw was 
taken from the parameter distribution of the COPD-related mortality rate. 
 
 
2.8 Model implementation and internal validation 
A detailed mathematical description of the model and its implementation in Mathematica [35] 
is given in Appendix D. During the development of the model, the internal validity of the 
model was secured by performing fifteen different model checks to prevent internal 
inconsistencies. The performed model checks, results and possible actions to resolve the 
problem are shown in Appendix E. 
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3. Reference and intervention scenarios 
 
With the extended model it is possible to estimate the long-term effectiveness and cost-
effectiveness of pharmaceutical and non-pharmaceutical COPD interventions that have an 
effect on disease progression, quality of life, mortality and/or the frequency and severity of 
exacerbations. Thus consistent and long-term cost-effectiveness outcomes can be obtained 
for a range of interventions.  
The effect of interventions is modeled by means of multiplicators. These multiplicators are 
applied to the parameters that change in an intervention scenario. The intervention therefore 
needs to be specified in terms of the relative change in disease progression, quality of life, all-
cause mortality or exacerbation frequency compared to the reference scenario.  
To illustrate the potential use of the model three different types of interventions for COPD are 
simulated. All scenario analyses were performed using a cohort of COPD patients, thus 
assuming no newborns and no new incidence of COPD. 
 
 
3.1 Reference scenario 
Chapter two described the input parameter for the reference scenario. Because input 
parameters are as far as possible based on data sources in which patients received minimal 
treatment, the reference scenario in our model represents the COPD population in the 
Netherlands receiving minimal intervention. A change in certain model parameters due to an 
intervention can be evaluated in so-called scenario analyses. Comparison of these scenarios 
with the projections for the reference scenario, gives an estimate of the impact of the 
intervention compared to minimal intervention.  
 
 
3.2 Scenario one and two: pharmacotherapy 
The first two scenarios assumed implementation of a combination of a long-acting beta-
agonist and inhaled corticosteroid (ICS/LABA=salmeterol/fluticasone) or implementation of a 
long-acting beta-agonist alone (LABA=salmeterol) for all COPD patients in the GOLD stages 
moderate and severe COPD. Both pharmacotherapies were assumed to affect lung function 
decline, exacerbation frequency and mortality. Data on short-term effectiveness, i.e. three 
years, were obtained from the TORCH trial [36]. The relative risks or the calculated ratio of 
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the effect for lung function decline, exacerbation frequency and all-cause mortality compared 
to placebo are shown in table 3.1. 
 
Table 3.1: Short-term effectiveness of a long-acting beta-agonist or a combined long-acting 
beta-agonist and inhaled corticosteroid based on the TORCH trial[36], relative risks or ratios 
of the effect in the active treatment group compared to placebo (95% confidence interval) 
 Salmeterol (n=1521) Combination 
Salmeterol/fluticasone 
(n=1533) 
Annual decline in lung function  0.67 (0.51-0.82) 0.60 (0.45-0.76) 
Total exacerbations 0.85 (0.78-0.93) 0.75 (0.69-0.81) 
All-cause mortality at 3 yr 0.879 (0.729-1.061) 0.825 (0.681-1.002) 
 
As the three parameters are related, i.e. a reduction in lung function decline has an effect on 
exacerbation frequency and mortality, we modeled the effectiveness of the interventions in 
three steps. We first applied the effect of the treatment options on lung function decline. We 
then studied what effect this had on the annual exacerbation rate over three years, the 
duration of the trial. If the effect was smaller than the effect on exacerbations given in the 
table, we moved to step 2 and adjusted the effect of the treatment options on exacerbation 
frequency till the magnitude of the effect seen in the trial. After that the effect of the first two 
steps on all-cause mortality was determined. In step 3 we adjusted the effect on mortality till 
the effect seen in the trial.  
Costs of the two pharmacotherapies were obtained from the Dutch Pharmacotherapeutic 
Compass [37]. Based on the assumption that patients receive four prescriptions per year, the 
total annual costs for salmeterol/fluctisone and salmeterolwere estimated to be €773 and 
€397, respectively (including VAT and four times the mark-up to cover pharmacy expenses of 
on average €7,00). For scenario one and two we assumed continuous implementation, i.e. 
the effects and the intervention costs are applied each year. The chosen time horizon was 10 
years. 
 
 
 
 
 
 28 
3.3 Scenario three: smoking cessation 
The third scenario assumed increased use of smoking cessation support by smoking COPD 
patients. As the current guidelines recommend that all smoking COPD patients should be 
offered the most intensive smoking cessation intervention feasible, we choose to model the 
implementation of intensive counseling (>90 minutes) in combination with pharmacotherapy 
(NRT, bupropion or nortriptyline).  
The 12 month continuous abstinence rate for intensive counseling plus pharmacotherapy was 
estimated to be 10.9% (95%: 6.9-15.0) higher than the abstinence rate for usual care [38]. 
Intervention costs of intensive counseling plus pharmacotherapy were estimated to be €305 
(price level 2007) [38]. The implementation of smoking cessation interventions for COPD 
patients was modelled by replacing the smoking cessation rates of usual care with the higher 
smoking cessation rates of the intervention for one year, for all smoking COPD patients. The 
effects of smoking cessation were modelled as a one-time increase in FEV1% predicted in the 
year of smoking cessation followed by a lower annual decline in FEV1% predicted based on 
the Lung Health Study (see Table A6 in Appendix A)[39] and reduced mortality due to COPD 
and other smoking-related diseases. The effects of one-year implementation of intensive 
counselling plus pharmacotherapy were evaluated over a time horizon of 20 years.  
 
 
3.4 Scenario four: pulmonary rehabilitation 
In scenario four we simulated implementation of a pulmonary rehabilitation program, which 
was assumed to affect quality of life. We modeled implementation of a two-year 
interdisciplinary community-based pulmonary rehabilitation program for all patients with 
moderate and severe COPD. The gain in QALYs for the intervention group over two years 
was assumed to be 0.08 (95% CI: -0.01-0.18) based on the INTERCOM trial. Two-year costs 
of the program were €1,490 [40]. Effects of the program were assumed to remain present one 
year after the intervention period. This means that effects were implemented for three years, 
intervention costs for two years. The time horizon for the evaluation of pulmonary 
rehabilitation was shorter than for the other scenarios, 5 years.  
 
 
Results of the model simulations for the four different scenarios were compared to the 
reference scenario, representing minimal intervention, to estimate the number of (quality-
adjusted) life years gained, the number of exacerbations avoided, the incremental 
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intervention costs and the savings in COPD-related health care costs. Health outcomes were 
discounted by 1.5%, costs by 4% as recommended by Dutch guidelines [41]. The cost per 
quality-adjusted life year gained was calculated as the ratio of total intervention costs minus 
savings in COPD-related healthcare costs due to the intervention compared to the reference 
scenario divided by the cumulative quality-adjusted life years gained compared to the 
reference scenario. The cost per exacerbation avoided was calculated as the ratio of total 
intervention costs minus savings in COPD-related healthcare costs compared to the 
reference scenario divided by the cumulative exacerbations avoided compared to the 
reference scenario representing minimal intervention.    
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4. Sensitivity analyses 
 
For all scenario analyses two types of sensitivity analyses were performed. First, one-way 
sensitivity analyses were performed for a number of key model assumptions and key 
parameter values including the values of parameters for which a probabilistic approach was 
not appropriate, for instance the discount rates. If possible, the input parameters evaluated 
were varied using the lower and upper limit of their 95% confidence interval.  
Second, probabilistic sensitivity analysis was performed for most input parameters 
simultaneously, using Monte Carlo simulation and drawing from probability distributions for 
each parameter in each simulation to result in confidence intervals around the outcome 
parameters. This required building a shell for Monte Carlo simulation around the model. The 
probability distributions on input parameters are described in section 4.2. To estimate the 
uncertainty around the cost-effectiveness of the scenarios we used 1000 model simulations in 
the probabilistic sensitivity analysis.  
   
4.1 One-way sensitivity analyses  
One-way sensitivity analyses were performed on the following parameters.  
 
a. Change of lung function over time, annual decline in FEV1% predicted. 
We investigated the effect of a 50% higher or lower annual decline in FEV1% predicted.  
1.  50% lower annual decline in FEV1% predicted 
2. 50% higher annual decline in FEV1% predicted 
 
b. The baseline exacerbation frequencies per COPD severity stage 
We performed two sensitivity analyses using the lower and upper limit of the 95% uncertainty 
interval around the estimated mean exacerbation frequency per GOLD stage.  
1. Lower 95% CI limits for each GOLD stage from the table below (or paragraph 2.2) 
2.  Upper 95% CI limits for each GOLD stage from the table below (or paragraph 2.2)
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Table 4.1: Exacerbation frequencies per GOLD stage with 95% uncertainty limits 
GOLD stage Total exacerbations Severe exacerbations 
 
Mean 95% lower 
limit 
95% 
upper limit 
Mean 95% lower 
limit 
95% upper 
limit 
I, Mild COPD  0.82 0.46 1.49 0.11 0.02 0.56 
II, Moderate COPD  1.17 0.93 1.50 0.16 0.07 0.33 
III, Severe COPD  1.61 1.51 1.74 0.22 0.20 0.23 
IV, Very severe COPD  2.10 1.51 2.94 0.28 0.14 0.63 
 
c. The case-fatality of a COPD exacerbation 
We investigated the effect of no case-fatality of a COPD exacerbation or using the lower and 
upper limit of the 95% confidence interval of the estimated mean case fatality of a COPD 
exacerbation of 15.6%. 
1 No case-fatality of a COPD exacerbation 
2 Lower 95% CI limit: 10.9%  
3 Upper 95% CI limit: 20.3%  
 
d. Decline in lung function due to an exacerbation 
We performed three additional analyses using no decline in lung function due to an 
exacerbation and using the lower and upper limit of the 95% confidence interval of the 
estimated mean decline in lung function due an exacerbation of -0.19% predicted. 
1 No decline in lung function due to an exacerbation 
2 Lower 95% CI limit: -0.092% predicted 
3 Upper 95% CI limit: -0.288% predicted 
 
e. Utility decrement due to an exacerbation 
We investigated the effect of using the lower and upper limits of the 95% confidence intervals 
of the estimated mean utility decrement due to an moderate exacerbation, 1.66% (95% CI: 
1.23-2.09) of the baseline utility value in a particular COPD severity stage  and the calculated 
mean utility decrement for a severe exacerbation, 4,82% (95% CI: 3.11-6.53), which resulted 
in the absolute utility decrements as shown in the table below. 
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Table 4.2: Absolute disutilities for a moderate and severe exacerbation according to GOLD 
including uncertainty  
GOLD stage Moderate exacerbation Severe exacerbation 
 
Mean 95% lower 
limit 
95% 
upper limit 
Mean 95% lower 
limit 
95% upper 
limit 
I, Mild COPD  0.0149 0.0110 0.0188 0.0432 0.0279 0.0585 
II, Moderate COPD  0.0125 0.0093 0.0158 0.0364 0.0235 0.0493 
III, Severe COPD  0.0124 0.0092 0.0156 0.0361 0.0233 0.0488 
IV, Very severe COPD  0.0091 0.0068 0.0115 0.0265 0.0171 0.0358 
 
1.  Lower 95% CI limits: 1.23% from the baseline utility value in a particular COPD 
severity stage for a moderate and 3.11% for a severe COPD exacerbation 
2.  Lower 95% CI limits: 2.09% from the baseline utility value in a particular COPD 
severity stage for a moderate and 6.53% for a severe COPD exacerbation 
 
f. Costs of a COPD exacerbation 
We performed additional analyses using the lower and upper limit of the 95% confidence 
intervals of the estimates of the costs of a moderate exacerbation, €94 (95% CI: 86-102) and 
a severe exacerbation, €4100 (95% CI: 2348-5852) 
1. Lower 95% CI limits: €86 for a moderate and €2348 for a severe exacerbation 
2. Upper 95% CI limits: €102 for a moderate and €5852 for a severe exacerbation 
 
g. Mean utility scores by COPD severity stage according to GOLD  
We performed two sensitivity analyses using 10% lower and 10% higher utility values per 
GOLD stage.  
1. 10% lower utility values in each GOLD stage  
2. 10% higher utility values in each GOLD stage 
 
h. Usual care stop rate for smoking COPD patients 
In the model, the stop rate among smoking COPD patients in the reference scenario is equal 
to the stop rate for smokers in the general population. Based on the gender- and age 
distribution of the COPD population, the mean stop rate for COPD patients receiving usual 
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care is 7.6%. Based on an earlier performed meta-analysis on smoking cessation 
interventions in COPD patients, we feel that the stop rate for usual care in smoking COPD 
patients may be lower. However, there are virtually no studies on stop rates in usual care in 
the Netherlands. There is one study, the SMOCC study that reported 1.4% [38]. In this 
sensitivity analysis we investigated the impact of using the lower stop rate for smoking COPD 
patients. 
1.  Using a usual care stop rate for smoking COPD patients of 1.4% 
  
i. Costs of the intervention 
For this sensitivity analysis we investigated the impact of a 10% reduction or increase in 
intervention costs. 
1. 10% reduction in intervention costs 
2. 10% increase in intervention costs 
 
j. Discount rates 
We performed additional analyses using different discount rates than in the reference 
scenario analyses in which we used 1.5% for effects and 4% for costs, which are the Dutch 
standard rates[41]. 
1. 0% for effects and 0% for costs 
2. 4% for effects and 4% for costs 
 
k. Time horizon 
The analysis for the reference scenario was performed using a time horizon of ten years for 
the scenarios on salmeterol/fluticasone and salmeterol, twenty years for smoking cessation 
and five years for pulmonary rehabilitation. We performed additional analyses using a shorter 
time horizon or a longer time horizon. 
1. Time horizon of 5, 10 or 2 years 
2. Time horizon of 20, 30 or 10 years  
 
 
4.2 Probabilistic sensitivity analyses. 
In order to assess the impact of uncertainty around the different input parameters on the 
outcomes, a probabilisitic sensitivity analysis (PSA) was performed. A probabilistic sensitivity 
analysis considers the uncertainty around the input parameters simultaneously by using pre-
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specified distributions for these parameters instead of point estimates. Table 4.3 lists all 
model parameters that were varied in the probabilistic sensitivity analyses, as well as the 
variances used for this parameter. All parameters were assumed to be Normally distributed. 
The uncertainty around the probabilistic input parameters is propagated through the model 
simultaneously by conducting second-order Monte Carlo simulations. This means that for the 
uncertain parameters random draws are made from their probability distribution. The model is 
run for each set of parameters that is drawn and the outputs from each run are collected. The 
current analyses were based on 1000 iterations. The results of all iterations are plotted on a 
cost-effectiveness plane (CE-plane) to display the uncertainty around costs and effects. The 
information in the CE-plane is summarized in a cost-effectiveness acceptability curve 
(CEAC), which shows the probability that an intervention has a cost-effectiveness ratio below 
various threshold values of the willingness to pay for a quality-adjusted life year gained.  
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5. Results 
 
5.1 Description of the reference scenario of the model 
The COPD population in 2007, the starting year of the simulation consisted of 320,000 
patients above 45 years, 172,200 males and 149,100 females (Table 5.1). Thirty percent was 
smoker, while 64% was former smoker. The majority of patients had moderate COPD.  
 
Table 5.1: Description of the Dutch COPD population of 45 years and older in 2007, the 
starting year of the simulation.  
 Absolute number Percentage 
Total COPD population  321,300  
   
Males  172,200 53.6% 
Females 149,100 46.4% 
   
Never smokers 19,000 5.9% 
Current smokers 97,100 30.2% 
Former smokers 205,200 63.9% 
   
Mild COPD 85,400 26.6% 
Moderate COPD 177,800 55.3% 
Severe COPD 49,800 15.5% 
Very severe COPD 8,400 2.6% 
   
Total COPD-related health 
care costs 
€352.8 million  
- Exacerbation-related costs €238.1 million 67.5% 
- Costs for maintenance €114.8 million 32.5% 
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5.2 Cost-effectiveness results for the scenario’s  
In table 5.2 results of the cost-effectiveness of the four different scenarios are shown for the 
most realistic time horizons for each intervention, ten years for ICS/LABA and LABA, twenty 
years for smoking cessation and five years for pulmonary rehabilitation. Table 5.3 shows the 
cost-effectiveness of the four different scenarios for each of the three different time horizons, 
i.e. five, ten and twenty years, to be able to compare the interventions with each other using 
the same time horizon.  
 
Cost per QALY gained 
Of the two types of medications LABA or the combination of ICS/LABA, the combination 
resulted in the highest gain in QALYs and exacerbations avoided, but also in the highest 
intervention costs. Given a time horizon of ten years the cost-effectiveness ratios of both 
pharmacotherapies were relatively low, around or below €10,000 (Table 5.2). The cost per 
QALY gained for smoking cessation and pulmonary rehabilitation for a ten-year time horizon 
were €9,900 and €12,200, respectively (Table 5.3). 
A time horizon of ten years to evaluate smoking cessation interventions is however relatively 
short as the annual gain in QALYs is maximal around ten years. Based on a more realistic 
time horizon of twenty years, the cost-effectiveness ratio for implementation of intensive 
counseling plus pharmacotherapy was €6,100 per QALY gained (Table 5.2), compared to 
€6,400, €4,500 and €12,200 for ICS/LABA, LABA and pulmonary rehabilitation, respectively, 
using the same time horizon (Table 5.3).    
The 5-year cost-effectiveness ratio for pulmonary rehabilitation was estimated to be €12,200 
for two-year implementation of an interdisciplinary, community-based program for all patients 
with moderate and severe COPD. Using a five year time horizon, the cost per QALY gained 
for the other interventions were higher, especially for the smoking cessation intervention 
(Table 5.3).  
 
Cost per exacerbation avoided 
For both scenarios on increased implementation of pharmacotherapy, i.e. LABA or 
ICS/LABA, the cost per exacerbation avoided was around €2,000, irrespective of the time 
horizon. For the smoking cessation scenario only a time horizon of five years resulted in 
exacerbation avoided. For longer time horizons, the number of exacerbations in the smoking 
cessation arm was higher as patients live longer and are therefore longer at risk to get an 
exacerbation. As pulmonary rehabilitation was assumed to affect quality of life only, the 
 40 
scenarios on pulmonary rehabilitation did not result in a difference in exacerbations compared 
to the reference scenario and therefore the cost per exacerbation avoided could not be 
calculated. 
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5.3 Results for the one way sensitivity analysis for the four different scenario’s  
Results for the one way sensitivity analyses for each of the four scenarios are shown in 
Table 5.4 to Table 5.7.  
 
Cost per QALY gained 
For the scenarios on ICS/LABA and LABA, costs per QALY gained were most sensitive to 
the time horizon chosen. Of all sensitivity analyses on exacerbation-related input 
parameters changes in the baseline exacerbation frequencies had the highest influence 
on the cost per QALY gained. For the scenario on pharmacotherapy for smoking 
cessation the time horizon chosen also had the highest impact on the cost per QALY 
gained. Of the other sensitivity analyses the baseline exacerbation frequencies and a 
lower usual care stop rate for smoking COPD patients had the highest influence on the 
cost-effectiveness ratio.    
For the scenario on pulmonary rehabilitation a 10% reduction or increase in the 
intervention costs and a 10% reduction or increase in the utility values for the COPD 
GOLD stages had the largest influence, while a two-year time horizon increased the costs 
per QALY for implementation of an interdisciplinary community-based program from 
€12,200 to €17,400. 
 
Cost per exacerbation avoided 
For the two medication scenarios the cost per exacerbation avoided were rather stable 
and remained below €5,000 per exacerbation avoided in all sensitivity analyses.  
For the smoking cessation scenario cost per exacerbation avoided were negative due to a 
higher number of exacerbations in the intervention scenario compared to the reference 
scenario for all sensitivity analyses, except for a five year time horizon. As mentioned the 
cost per exacerbation avoided could not be calculated for the pulmonary rehabilitation 
program as no exacerbations were avoided. 
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Table 5.4: Sensitivity analyses for 10 year implementation of a combination of ICS/LABA, 
i.e. salmeterol/ fluticasone, for the cohort of Dutch COPD patients with moderate or 
severe COPD in 2007, time horizon 10 years, € 
 Cost per 
exacerbation 
avoided 
Costs per 
QALY 
gained 
Standard comparison of the intervention scenario with the 
reference scenario 
2,100 10,100 
   
a. Annual decline in FEV1% predicted   
1. 50% lower annual decline 2,300 11,300 
2.  50% higher annual decline 1,900 8,900 
b. Baseline exacerbation frequencies    
1. lower 95% CI limits for all four GOLD stages 2,700 12,900 
2. upper 95% CI limits for all four GOLD stages 1,700 6,900 
c. Case fatality of a COPD exacerbation   
1. lower 95% CI limit: 10.9%  2,000 10,900 
2. upper 95% CI limit: 20.3% 2,200 9,400 
d. Decline in lung function due to an exacerbation   
1. lower 95% CI limit: -0.092% predicted 2,200 10,400 
2. upper 95% CI limit: -0.288% predicted 2,100 9,900 
e. Utility decrement due to an exacerbation   
1. lower 95% CI limit: 1.23% for moderate, 3.11% for severe 
exacerbation 
2,100 10,300 
2. upper 95% CI limit: 2.09% for moderate, 6.53% for severe 
exacerbation 
2,100 9,900 
f. Costs of an exacerbation   
1. Lower 95% CI limit: €86 for moderate, €2348 for severe 
exacerbation 
2,300 11,200 
2. Upper 95% CI limit: €102 for moderate, €5852 for severe 
exacerbation 
1,900 9,000 
g. Utility scores for the COPD GOLD stages   
1. 10% reduction in utility score in each GOLD stage 2,100 11,200 
2. 10% increase in utility score in each GOLD stage 2,100 9,200 
h. Lower usual care stop rate for smoking COPD patients   
1. Using a stop rate of 1.4%  2,100 10,100 
i. Costs of the intervention   
1. 10% reduction in intervention costs 1,900 8,900 
2. 10% increase in intervention costs 2,400 11,300 
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Cost per 
exacerbation 
avoided 
Costs per 
QALY 
gained 
j. Other discount rates   
1. 0% effects, 0% costs 2,300 10,800 
2. 4% effects, 4% costs 2,300 11,600 
k. Different time horizon   
1. Two times shorter time horizon than base case (=5 years) 2,000 18,600 
2. Two times longer time horizon than base case (=20 years) 2,400 6,400 
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Table 5.5: Sensitivity analyses for 10 year implementation of LABA, i.e. salmeterol for the 
cohort of Dutch COPD patients with moderate or severe COPD in 2007, time horizon ten 
years, € 
 Cost per 
exacerbation 
avoided 
Costs per 
QALY gained 
Standard comparison of the intervention scenario with the 
reference scenario 
1,800 7,100 
   
a. Annual decline in FEV1% predicted   
1. 50% lower annual decline 2,000 8,200 
2.  50% higher annual decline 1,600 6,100 
b. Baseline exacerbation frequencies    
1. lower 95% CI limits for all four GOLD stages 2,300 9,000 
2. upper 95% CI limits for all four GOLD stages 1,400 4,900 
c. Case fatality of a COPD exacerbation   
1. lower 95% CI limit: 10.9%  1,700 7,600 
2. upper 95% CI limit: 20.3% 1,900 6,700 
d. Decline in lung function due to an exacerbation   
1. lower 95% CI limit: -0.092% predicted 1,800 7,300 
2. upper 95% CI limit: -0.288% predicted 1,700 6,900 
e. Utility decrement due to an exacerbation   
1. lower 95% CI limit: 1.23% for moderate, 3.11% for severe 
exacerbation 
1,800 7,200 
2. upper 95% CI limit: 2.09% for moderate, 6.53% for severe 
exacerbation 
1,800 7,000 
f. Costs of an exacerbation   
1. Lower 95% CI limit: €86 for moderate, €2348 for severe 
exacerbation 
2,000 8,000 
2. Upper 95% CI limit: €102 for moderate, €5852 for severe 
exacerbation 
1,500 6,200 
g. Utility scores for the COPD GOLD stages   
1. 10% reduction in utility score in each GOLD stage 1,800 7,900 
2. 10% increase in utility score in each GOLD stage 1,800 6,500 
h. Lower usual care stop rate for smoking COPD patients   
1. Using a stop rate of 1.4%  1,800 7,100 
i. Costs of the intervention   
1. 10% reduction in intervention costs 1,500 6,200 
2. 10% increase in intervention costs 2,000 8,000 
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Cost per 
exacerbation 
avoided 
Costs per 
QALY gained 
j. Other discount rates   
1. 0% effects, 0% costs 2,000 7,600 
2. 4% effects, 4% costs 1,900 8,100 
k. Different time horizon   
1. Two times shorter time horizon than base case (=5 years) 1,600 13,200 
2. Two times longer time horizon than base case (=20 years) 2,100 4,500 
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Table 5.6: Sensitivity analyses for 1 year implementation of intensive counseling plus 
pharmacotherapy for smoking cessation for all Dutch smoking COPD patients in 2007, 
time horizon 20 years, € 
 Cost per 
exacerbation 
avoided 
Costs per 
QALY 
gained 
Standard comparison of the intervention scenario with the 
reference scenario 
Dominated 6,100 
   
a. Annual decline in FEV1% predicted   
1. 50% lower annual decline Dominated 6,300 
2.  50% higher annual decline Dominated 5,800 
b. Baseline exacerbation frequencies    
1. lower 95% CI limits for all four GOLD stages Dominated 5,700 
2. upper 95% CI limits for all four GOLD stages Dominated 10,100 
c. Case fatality of a COPD exacerbation   
1. lower 95% CI limit: 10.9%  Dominated 6,000 
2. upper 95% CI limit: 20.3% Dominated 6,100 
d. Decline in lung function due to an exacerbation   
1. lower 95% CI limit: -0.092% predicted Dominated 6,000 
2. upper 95% CI limit: -0.288% predicted Dominated 6,100 
e. Utility decrement due to an exacerbation   
1. lower 95% CI limit: 1.23% for moderate, 3.11% for severe 
exacerbation 
Dominated 6,100 
2. upper 95% CI limit: 2.09% for moderate, 6.53% for severe 
exacerbation 
Dominated 6,100 
f. Costs of an exacerbation   
1. Lower 95% CI limit: €86 for moderate, €2348 for severe 
exacerbation 
Dominated 6,000 
2. Upper 95% CI limit: €102 for moderate, €5852 for severe 
exacerbation 
Dominated 6,200 
g. Utility scores for the COPD GOLD stages   
1. 10% reduction in utility score in each GOLD stage Dominated 6,700 
2. 10% increase in utility score in each GOLD stage Dominated 5,500 
h. Lower usual care stop rate for smoking COPD patients   
1. Using a stop rate of 1.4%  Dominated 4,700 
i. Costs of the intervention   
1. 10% reduction in intervention costs Dominated 5,500 
2. 10% increase in intervention costs Dominated 6,600 
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Cost per 
exacerbation 
avoided 
Costs per 
QALY 
gained 
j. Other discount rates   
1. 0% effects, 0% costs Dominated 5,600 
2. 4% effects, 4% costs Dominated 7,500 
k. Different time horizon   
1. Two times shorter time horizon than base case (=5 years) 31,900 26,800 
2. Two times longer time horizon than base case (=20 years) Dominated 9,900 
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Table 5.7: Sensitivity analyses for 2 year implementation of an interdisciplinary, 
community-based pulmonary rehabilitation program for all Dutch COPD patients with 
moderate and severe COPD in 2007, time horizon of five years, € 
 Cost per 
exacerbation 
avoided 
Costs per  
QALY  
gained 
Standard comparison of the intervention scenario with the 
reference scenario 
- 12,200 
   
b. Baseline exacerbation frequencies    
1. lower 95% CI limits for all four GOLD stages - 12,100 
2. upper 95% CI limits for all four GOLD stages - 12,400 
e. Utility decrement due to an exacerbation   
1. lower 95% CI limit: 1.23% for moderate, 3.11% for severe 
exacerbation 
- 12,100 
2. upper 95% CI limit: 2.09% for moderate, 6.53% for severe 
exacerbation 
- 12,300 
g. Utility scores for the COPD GOLD stages   
1. 10% reduction in utility score in each GOLD stage  13,600 
2. 10% increase in utility score in each GOLD stage  11,100 
i. Costs of the intervention   
1. 10% reduction in intervention costs - 11,000 
2. 10% increase in intervention costs - 13,400 
j. Other discount rates   
1. 0% effects, 0% costs - 12,300 
2. 4% effects, 4% costs - 12,500 
k. Different time horizon   
1. Two times shorter time horizon than base case (=5 years) - 17,400 
2. Two times longer time horizon than base case (=20 years) - 12,200 
*Sensitivity analyses a, c, d, f and h are not shown as pulmonary rehabilitation did not influence 
these parameters and the cost per QALY remained €12,200 in these analyses 
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5.4 Results for the probabilistic sensitivity analysis for the four different scenario’s  
 
Scenario 1: Implementation of a combination of ICS/LABA 
Figure 5.1 shows the cost-effectiveness plane for 10 year implementation of a 
combination of ICS/LABA to all Dutch COPD patients with moderate and severe COPD 
evaluated over a ten year time horizon. All 1000 model simulations felt in the upper right 
quadrant indicating more QALYs and higher costs compared to the reference scenario.  
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Figure 5.1: Cost-effectiveness plane for ten year implementation of a combination of 
ICS/LABA to all Dutch COPD patients with moderate and severe COPD, time horizon ten 
years, discount rates 1.5% effects, 4% costs 
 
 
The accompanying acceptability curve (Figure 5.2) showed that the probability of a 
combination of ICS/LABA to be cost-effective was 52% for a maximum willingness-to-pay 
of €10,000 and 100% for a ceiling ratio of €20,000.  
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Figure 5.2: Acceptability curve for ten year implementation of a combination of ICS/LABA 
for all Dutch COPD patients with moderate and severe COPD, time horizon 10 years, 
discount rates, 1.5% effects, 4% costs.  
 
 
 
 
Scenario two: Implementation of LABA 
Figure 5.3 shows the cost-effectiveness plane for 10 year implementation of a LABA to all 
Dutch COPD patients with moderate and severe COPD evaluated over a ten year time 
horizon. Again, all 1000 model simulations felt in the upper right quadrant indicating more 
QALYs and higher costs compared to the reference scenario.  
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Figure 5.3: Cost-effectiveness plane for ten year implementation of a LABA to all Dutch 
COPD patients with moderate and severe COPD, time horizon ten years, discount rates 
1.5% effects, 4% costs 
 
 
The acceptability curve showed that the probability of the LABA salmeterol to be cost-
effective was 96% and 100% for a maximum willingness-to-pay of €10,000 and €20,000, 
respectively (Figure 5.4).  
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Figure 5.4: Acceptability curve for ten year implementation of a LABA (=salmeterol) for all 
Dutch COPD patients with moderate and severe COPD, time horizon 10 years, discount 
rates, 1.5% effects, 4% costs. 
 
 
Scenario three: implementation of pharmacotherapy for smoking cessation 
Figure 5.5 shows the cost-effectiveness plane for 1 year implementation of intensive 
counseling plus pharmacotherapy for smoking cessation for all smoking COPD patients 
evaluated over a twenty year time horizon. Of the 1000 model replications 99.9% felt in 
the upper right quadrant indicating more QALYs and higher costs compared to the 
reference scenario, while in 0.1% of the simulations the scenario had lower QALYs, but 
higher costs than the reference scenario.  
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Figure 5.5: Cost-effectiveness plane for one year implementation of intensive counseling 
plus pharmacotherapy for smoking cessation for all smoking COPD patients, time horizon 
twenty years, discount rates 1.5% effects, 4% costs 
 
 
The acceptability curve showed that the probability of the smoking cessation intervention 
to be cost-effective was 91% for a maximum willingness-to-pay of €10,000 and 98% for a 
ceiling ratio of €20,000.  
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Figure 5.6: Acceptability curve for one year implementation of intensive counseling plus 
pharmacotherapy for smoking cessation for all smoking COPD patients, time horizon 
twenty years, discount rates 1.5% effects, 4% costs 
 
 
 
Scenario four: implementation of community-based pulmonary rehabilitation program 
Figure 5.7 shows the cost-effectiveness plane for two year implementation of an 
interdisciplinary community-based pulmonary rehabilitation program for all patients with 
moderate and severe COPD evaluated over a five year time horizon. 96% of the model 
simulations felt in the upper right quadrant indicating more QALYs and higher costs 
compared to the reference scenario.  
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Figure 5.7: Cost-effectiveness plane for two year implementation of interdisciplinary 
community-based pulmonary rehabilitation to all Dutch COPD patients with moderate and 
severe COPD, time horizon five years, discount rates 1.5% effects, 4% costs 
 
The acceptability curve showed that the probability of an interdisciplinary community-
based pulmonary rehabilitation program to be cost-effective was 33% for a maximum 
willingness-to-pay of €10,000 and 76% for a ceiling ratio of €20,000.  
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Figure 5.8: Acceptability curve for two year implementation of interdisciplinary community-
based pulmonary rehabilitation for all patients with moderate and severe COPD, time 
horizon five years, discount rates 1.5% effects, 4% costs 
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6. Discussion 
This study aimed at improving our previously published COPD model by including 
exacerbations and making the model stochastic. To illustrate the potential of the model 
four different COPD interventions were evaluated. The outcomes of these so-called 
scenario analyses were only illustrative and no definite conclusions can be drawn from the 
results for the following two reasons. For three scenario analyses short-term effectiveness 
used to fill the model was based on one study, i.e. the TORCH trial [36] or the INTERCOM 
trial [42]. To obtain more representative results effectiveness should be based on 
systematic reviews as for the smoking cessation scenario [38]. Second, we did not take 
into account realistic percentages of patients receiving the interventions, but applied the 
effects to all Dutch moderate or severe COPD patients or all smoking COPD patients. 
This is not realistic as for instance in the smoking cessation intervention, not all smoking 
COPD patients are willing to participate in a smoking cessation intervention. The 
percentage of smoking COPD patients reporting a willingness to stop smoking within six 
months is about fifty percent [43,44]. The same applies to the pulmonary rehabilitation 
scenario as not all moderate and severe COPD patients are eligible for such a program. 
For example, the INTERCOM program was indicated for patients with an impaired 
exercise capacity, only. To give more realistic estimates of the results in absolute 
numbers, reliable estimates of the percentage of patients using the interventions would be 
needed. These percentages however, do not substantially affect the estimates of the cost 
per QALY gained or the cost per exacerbation avoided. A different indication however, 
does affect the cost-effectiveness.  
   
By choosing four completely different scenarios we tried to emphasize that the extended 
model can be used to evaluate a wide range of interventions. The model can be used to 
evaluate interventions that have an effect on lung function decline, quality of life, mortality 
and/or the frequency and severity of exacerbations. In our scenario analyses, both 
pharmacotherapies are assumed to affect disease progression, exacerbation frequency 
and all-cause mortality. The smoking cessation intervention is assumed to affect disease 
progression only. Indirectly, this affects mortality as patients reach the more severe stages 
of COPD later than they would if they would not have stopped smoking. Mortality is also 
directly reduced because within each severity stage smokers who quit get the lower 
mortality risk of former smokers. A possible positive effect of smoking cessation on 
exacerbation frequency could have been included in the scenario analysis, but no data 
are available which could be used as input for the model. The third type of scenario 
analysis, implementation of a pulmonary rehabilitation program, was assumed to have an 
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effect on quality of life. The model can also assess the impact of smoking cessation in the 
general population on COPD incidence. However, the current analysis was restricted to a 
cohort analysis among COPD patients already diagnosed. 
 
Three different aspects with respect to the intervention scenarios should be kept in mind 
when comparing the cost-effectiveness outcomes of the four scenario analyses with each 
other. These aspects have a substantial impact on the absolute numbers of exacerbations 
avoided, QALYs gained, intervention costs and savings in COPD-related healthcare costs 
but also on the cost-effectiveness ratios. First, due to the different types of interventions 
used, the most realistic time horizon to use was different for each intervention. For 
pharmacotherapies ten years seemed a realistic time horizon, while for smoking cessation 
a ten-year time horizon was relatively short as the annual gain in QALYs was maximal 
around ten years. For pulmonary rehabilitation a ten-year time horizon is too long and a 
five-year time horizon seemed more appropriate. Second, the duration of implementation 
was different for all interventions. For pharmacotherapies we assumed that both ICS and 
LABA/ICS were used as maintenance therapy for the whole time horizon, i.e. continuous 
implementation. For the smoking cessation scenario however, we only used an 
implementation period of one year because it is not realistic to assume that all COPD 
patients receive smoking cessation interventions repeatedly each year. The scenario on 
pulmonary rehabilitation was based on a two-year trial, but we assumed the quality of life 
to be improved for three years. Finally, the patient population to which the intervention 
was offered was different for the smoking cessation scenario. Both scenarios on 
pharmacotherapies and pulmonary rehabilitation are assumed to be implemented for all 
moderate and severe patients (n=227,600), while the smoking cessation intervention was 
assumed to be given to all smoking patients, regardless of their disease severity 
(n=97,100). The shorter duration of the implementation period and the smaller patient 
population to which the intervention was offered explains why for example the absolute 
gain in QALY in the smoking cessation scenario was substantially lower.     
 
For all four scenario analyses we performed extensive one-way sensitivity analyses on the 
new exacerbation-related model parameters and on parameters for which a probabilistic 
sensitivity analysis is not appropriate, such as discount rates. One-way sensitivity 
analyses on the model parameters that were already included in the 2005 version of the 
model, such as the estimated severity distribution of the COPD population at baseline, the 
decline in lung function and mortality were performed previously [1]. In the 2005 version 
the distribution of the incidence over the severity stages had the largest influence on the 
projections but as the current scenario analyses are based on a cohort assuming no new 
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incidence, the distribution of the incidence plays no role in the current analyses. As the 
decline in FEV1% predicted is the parameter defining disease progression, a very 
important parameter in our model, we also included a one-way sensitivity analysis on this 
parameter. In the 2005 version of the model, a 10% lower or higher annual decline in 
FEV1% predicted had a moderate influence on the projections of the prevalence and costs 
over twenty five years. In the current version comparing intervention scenarios with the 
reference scenario the sensitivity analyses on decline did not have a large influence. Four 
all four scenarios the time horizon chosen had the largest influence on the results. For the 
scenarios on pharmacotherapy and smoking cessation baseline exacerbation frequencies 
also influenced the results substantially. The latter however are well-based estimates 
obtained from a systemic review (see Appendix B). For the smoking cessation 
intervention, a lower stop rate for usual care also influenced the cost per QALY. However, 
because of the lack of studies reflecting usual care with respect to smoking cessation in 
COPD, the abstinence rate of usual care used in the sensitivity analyses was based on 
only one study.  
 
Compared to the 2005 model, the extended model can generate uncertainty around the 
estimated results using probabilistic sensitivity analyses. The overall uncertainty around 
the estimates of the outcomes was relatively limited as in almost all cost-effectiveness 
planes all model iterations fell in one single quadrant, the north-east quadrant, indicating 
more effect but higher costs. Although the individual uncertainty around the gain in QALYs 
and the costs was substantial, the positive correlation between effects and costs led to a 
smaller uncertainty around the incremental cost-effectiveness ratio than would be 
expected based on the uncertainty around the costs and effects alone. The uncertainty 
may also be reduced by the assumption of monotonicity that was applied to the utility 
values per GOLD stage and the costs per GOLD stage. For utility values for example this 
means that in each simulation the randomly drawn value for the utility weight for mild 
COPD needed to be higher than the randomly random drawn values for the utility weights 
for moderate and the value for moderate COPD needs to be higher then the value for 
severe COPD etc. Monotonicity was also indirectly included for the exacerbation 
frequencies as these were based on a regression equation. The impact of the assumption 
of monotonicity on the uncertainty needs to be explored in a future probabilistic sensitivity 
analysis without this assumption. However, this requires an adjustment of the structure of 
the model. Finally uncertainty is also influenced by the fact that we did not consider 
structural model uncertainty. A decrease in number of severe exacerbations for example 
always results in a reduction of the case fatality. The same is true for a reduction in 
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exacerbation frequency which always results in a gain in utility. However, assumptions like 
this are medically very plausible. 
 
A limitation of our model is of course that the severity and the progression of COPD are 
only defined by lung function, i.e. FEV1% predicted. The severity of COPD is not only 
determined by the degree of airflow limitation, but also by the severity of symptoms, 
especially breathlessness, the level of exercise impairment and the existence of co-
morbidities [4]. Celli et al showed that the BODE index, a simple multidimensional grading 
system using BMI, degree of airflow obstruction, dyspnea and exercise as parameters, 
was a better predictor of mortality in COPD patients than FEV1 alone [45]. But also other 
composite measures, such as the DOSE ( =Dyspnea, airflow Obstruction, Smoking status, 
Exacerbation frequency) and the ADO (=Age, Dyspnea, airflow Obstruction) seem to be 
better predictors of disease severity [46,47]. The same is true for disease progression. 
Other factors than the decline in lung function also influence the progression of the COPD 
[48]. However, parameters used in the BODE index for example are not all registered at 
general practices and in hospitals and therefore input data representative for the Dutch 
COPD population specified by BODE score are very difficult or impossible to obtain. For 
reasons of availability and simplicity the progression of COPD in the model is therefore 
only assumed to be dependent on the decline in FEV1% predicted, which in turn depends 
on gender, age, smoking status and FEV1% predicted. 
 
Up to now, six different COPD models, including our 2005 COPD model have been 
published [1,24,31,49-51]. All existing models are Markov models and comparable with 
respect to COPD severity based on FEV1% predicted, progression based on lung function 
decline, inclusion of exacerbations, distinction between at least severe and non-severe 
exacerbations and costs and utilities depending on severity stage and exacerbation 
frequency. Differences between the models are among others the number of COPD 
severity stages, inclusion of incidence and the allowance of backward transitions. 
Furthermore, some of the models are probabilistic [1,31,50], while others are not. Only the 
BOLD model described by Nielsen et al [51] and our model [1] are population-based 
models, representative for a total nationwide COPD population. However, the model of 
Nielsen et al is not stochastic. As our model is a probabilistic population-based model that 
includes new incidence, but can also be used for cohort analysis, it can be used to 
evaluate a wide range of interventions and assess the uncertainty around the results. 
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7. Conclusions  
The updated and adapted model described in this report is now well equipped to provide 
decision support with information about long-term health effects, costs and cost-
effectiveness of policy scenarios. Moreover it provides insight into the uncertainty of the 
outcomes.  
The model is innovative in that it combines modelling the incidence of COPD with the 
course of disease. This allows the identification of the most cost-effective interventions 
within the whole spectrum from prevention to care. Up to now this was impossible, 
because only fragmented information exists on the cost-effectiveness of COPD 
interventions. Moreover the information available is usually incomparable because of 
methodological differences. The current model also allows comparing interventions of 
different intensity and target group. It may stress the need for integrated approaches, 
since single programs will probably not reduce the burden of COPD sufficiently on a 
nationwide scale.  
The model has been developed without any industry support (funded by the RIVM, the 
Netherlands Asthma Foundation, the Dutch Ministry of Health, Welfare and Sports and the 
Erasmus University), and hence provides an independent tool for evaluation.  
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APPENDIX A: Input parameters 
 
Table A1: Dutch general population by gender and age*  
 Dutch population 2007 All-cause mortality as 
fraction of the total 
population 2006 
 Males Females Males Females 
0-4 494914 471967 0.0011 0.0009 
5-9 514058 491939 0.0001 0.0001 
10-14 504748 480989 0.0001 0.0001 
15-19 510433 488055 0.0003 0.0002 
20-24 488388 477647 0.0005 0.0002 
25-29 495146 494331 0.0005 0.0002 
30-34 534023 534125 0.0006 0.0004 
35-39 653937 641539 0.0008 0.0006 
40-44 663663 646161 0.0013 0.0010 
45-49 622404 613365 0.0021 0.0018 
50-54 569839 562389 0.0038 0.0030 
55-59 560626 550416 0.0061 0.0044 
60-64 464275 460263 0.0103 0.0064 
65-69 345852 361640 0.0168 0.0097 
70-74 270832 314133 0.0296 0.0162 
75-79 200533 274520 0.0515 0.0301 
80-84 123040 216114 0.0898 0.0560 
85+ 71803 189885 0.1780 0.1417 
* Aggregated into five years age classes 
 
Data source:  
Statistics Netherlands (CBS, 2006/2007) 
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Table A2: Proportion of never smokers, smokers and former smokers*  
 Males Females 
 Never 
smoker 
Current 
smoker 
Former 
smoker 
Never 
smoker 
Current 
smoker 
Former 
smoker 
0-4 1.00 0.00 0.00 1.00 0.00 0.00 
5-9 1.00 0.00 0.00 1.00 0.00 0.00 
10-14 0.93 0.06 0.00 0.94 0.06 0.00 
15-19 0.77 0.20 0.03 0.79 0.18 0.03 
20-24 0.60 0.31 0.09 0.64 0.27 0.09 
25-29 0.49 0.35 0.16 0.54 0.30 0.16 
30-34 0.45 0.35 0.20 0.52 0.29 0.19 
35-39 0.43 0.36 0.21 0.50 0.28 0.22 
40-44 0.38 0.36 0.26 0.39 0.31 0.30 
45-49 0.28 0.37 0.35 0.31 0.32 0.38 
50-54 0.21 0.35 0.44 0.29 0.31 0.40 
55-59 0.18 0.31 0.51 0.34 0.27 0.39 
60-64 0.17 0.25 0.58 0.41 0.21 0.38 
65-69 0.14 0.18 0.68 0.45 0.15 0.40 
70-74 0.12 0.14 0.73 0.46 0.13 0.41 
75-79 0.11 0.14 0.75 0.49 0.12 0.39 
80-84 0.10 0.15 0.75 0.53 0.10 0.37 
85+ 0.10 0.16 0.74 0.56 0.09 0.35 
* Aggregated into five years age classes 
 
Data source:  
STIVORO. Roken, de harde feiten: Volwassenen 2007. STIVORO, Den Haag 
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Table A3: Age-and gender specific COPD prevalence and incidence*  
 Prevalence as fraction of 
the general population 
Incidence as fraction of 
the general population 
 Males Females Males Females 
0-4 0.001 0.001 0.000 0.000 
5-9 0.001 0.001 0.000 0.000 
10-14 0.002 0.001 0.000 0.000 
15-19 0.003 0.002 0.000 0.000 
20-24 0.004 0.002 0.000 0.000 
25-29 0.005 0.003 0.000 0.000 
30-34 0.006 0.005 0.000 0.000 
35-39 0.007 0.007 0.001 0.001 
40-44 0.009 0.011 0.001 0.001 
45-49 0.013 0.016 0.002 0.002 
50-54 0.019 0.023 0.003 0.004 
55-59 0.029 0.032 0.005 0.005 
60-64 0.045 0.042 0.007 0.006 
65-69 0.071 0.053 0.009 0.007 
70-74 0.107 0.064 0.012 0.007 
75-79 0.146 0.072 0.013 0.006 
80-84 0.173 0.076 0.014 0.006 
85+ 0.174 0.074 0.014 0.005 
* Aggregated into five years age classes 
 
Adapted from data source: 
Van der Lucht F, Polder JJ. Van gezond naar beter. Kernrapport van de Volksgezondheid 
Toekomst Verkenning VTV-2010, versie 1.0, 25 maart 2010, RIVM, Bilthoven 
 
* Prevalence and incidence data in VTV 2010 are based on five general practice data 
bases, Continue Morbiditeits Registratie (CMR) Nijmegen, Landelijk Informatie Netwerk 
Huisartsenzorg (LINH), Registratienet Huisartsenpraktijken (RNH), Registratie Netwerk 
Universitaire Huisartspraktijken Leiden en omstreken (RNUH-LEO) and Transitieproject. 
For the Chronic Disease Model and therefore also for our COPD model, the prevalence 
and incidence estimates used are based on three data bases (CMR, RNH, RNUH-LEO). 
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 Table A4: Relative risks of smokers and former smokers to get COPD*  
 Males Females 
 Never 
smoker 
Current 
smoker 
Former 
smoker 
Never 
smoker 
Current 
smoker 
Former 
smoker 
0-4 1 1.9 1.7 1 1.7 1.5 
5-9 1 1.9 1.7 1 1.7 1.5 
10-14 1 1.9 1.7 1 1.7 1.5 
15-19 1 1.9 1.7 1 1.7 1.5 
20-24 1 1.9 1.7 1 1.7 1.5 
25-29 1 1.8 1.6 1 1.6 1.4 
30-34 1 2.0 1.8 1 1.8 1.6 
35-39 1 3.2 2.7 1 2.6 2.3 
40-44 1 5.1 4.1 1 4.0 3.4 
45-49 1 7.5 5.9 1 5.6 4.8 
50-54 1 9.8 7.9 1 7.7 6.4 
55-59 1 11.0 9.6 1 9.9 7.7 
60-64 1 11.7 10.3 1 11.3 8.3 
65-69 1 12.2 9.5 1 11.2 8.2 
70-74 1 12.5 8.5 1 10.0 7.4 
75-79 1 12.2 7.7 1 8.1 6.5 
80-84 1 11.0 7.0 1 6.1 5.4 
85+ 1 9.1 6.4 1 4.5 4.1 
* Aggregated into five years age classes 
 
Data source: 
- U.S. Department of Health and Human Services. The health consequences of smoking: 
a report of the Surgeon General. 2004, U.S. Department of Health and Human Services, 
centers for Disease Control and Prevention, National Center for Chronic Disease 
Prevention and Health promotion, Office on Smoking and Health, Atlanta 
- Van Oers JAM red. Gezondheid op koers? Volksgezondheid Toekomst Verkenning 
(VTV), 2002, RIVM, Bilthoven 
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Table A5: Age- and gender specific start, stop and restart probabilities for smoking, no 
uncertainty available* 
 Males Females 
 Start Stop Restart Start Stop Restart 
0-4 0 0 0 0 0 0 
5-9 0.005 0 0 0 0 0 
10-14 0.033 0.010 0.224 0.038 0.021 0.191 
15-19 0.052 0.042 0.401 0.052 0.078 0.369 
20-24 0.031 0.067 0.203 0.028 0.101 0.239 
25-29 0.009 0.077 0.081 0.007 0.104 0.098 
30-34 0.002 0.072 0.077 0.001 0.092 0.062 
35-39 0.003 0.060 0.073 0.001 0.067 0.060 
40-44 0.004 0.053 0.048 0.003 0.049 0.048 
45-49 0.005 0.056 0.028 0.004 0.048 0.032 
50-54 0.007 0.062 0.021 0.003 0.056 0.020 
55-59 0.006 0.068 0.012 0.002 0.064 0.013 
60-64 0.004 0.073 0.011 0.001 0.072 0.010 
65-69 0.003 0.072 0.010 0 0.080 0.009 
70-74 0.002 0.070 0.006 0 0.088 0.006 
75-79 0.001 0.073 0.003 0 0.096 0.004 
80-84 0 0.080 0.003 0 0.104 0.002 
85+ 0 0.086 0.003 0 0.109 0 
* Aggregated into five years age classes 
 
Data source: 
STIVORO. Roken, de harde feiten: Volwassenen 2003. STIVORO, Den Haag 
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 Table A6: Regression coefficients of the random effect model to predict lung function 
decline 
 β-Coefficient SE 
   
Intercept -20.9546 18.4636 
Year 0.2394 0.2473 
Smoking cessation 14.3188 1.0216 
Gender 7.3174 4.44 
Age 1.1132 0.7312 
Baseline FEV1% predicted 1.3646 0.2282 
Year*smoking cessation 0.4556 0.05597 
Year*gender -0.1562 0.03543 
Year*age -0.03144 0.00332 
Year*baseline FEV1% predicted 0.006027 0.001933 
Smoking cessation*gender 1.7297 0.2029 
Smoking cessation*baseline FEV1% 
predicted 
-0.1242 0.01092 
Gender*age -0.4038 0.1694 
Gender*baseline FEV1% predicted 0.02723 0.01347 
Age*baseline FEV1% predicted -0.01818 0.009069 
Age2 -0.01213 0.007189 
Age2*smoking cessation -0.00086 0.000143 
Age2*gender 0.004299 0.001674 
Age2*baseline FEV1% predicted 0.000197 0.000089 
 
Data source: 
Hoogendoorn M, et al. A dynamic population model of disease progression in COPD. 
2005, Eur Respir J, 26(2): 223-233 
 75
Table A7: COPD-related maintenance costs per patient by gender, age and disease 
severity  
 Mild COPD Moderate 
COPD 
Severe COPD Very severe 
COPD 
Males:     
45-49 47 58 65 96 
50-54 32 39 44 65 
55-59 31 39 43 65 
60-64 72 89 99 148 
65-69 135 167 187 277 
70-74 197 245 273 406 
75-79 346 430 480 712 
80-84 344 428 477 708 
85+ 659 820 913 1356 
     
Females:      
45-49 220 273 305 452 
50-54 270 335 374 555 
55-59 261 324 361 536 
60-64 263 327 364 541 
65-69 326 405 452 671 
70-74 292 364 405 602 
75-79 371 462 514 764 
80-84 407 507 564 838 
85+ 831 1034 1152 1711 
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Table A8: Mean utility scores by COPD severity stage according to GOLD 
GOLD stage: Mean utility score 
(SD) 
Mild COPD 0.8971 (0.1117) 
Moderate COPD 0.7551 (0.2747) 
Severe COPD 0.7481 (0.2991) 
Very severe COPD 0.5493 (0.3129) 
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Table A9: All-cause mortality, mortality attributable to COPD and mortality from other 
causes, specified by gender and age (per 1000 COPD patients)*  
 All-cause mortality Mortality attributable to 
COPD 
Mortality from other 
causes 
 Males Females Males Females Males Females 
0-4 90.9 102.6 90.9 102.6 0 0 
5-9 0 0 0 0 0 0 
10-14 1.9 0 1.9 0 0 0 
15-19 8.3 2.6 8.3 2.6 0 0 
20-24 9.2 1.8 9.2 1.8 0 0 
25-29 5.8 5.3 5.8 5.3 0 0 
30-34 5.8 5.2 5.8 5.2 0 0 
35-39 7.7 7.1 6.8 6.9 0.9 0.2 
40-44 9.9 9.2 8.6 8.4 1.3 0.8 
45-49 14.7 13.7 12.5 12.0 2.1 1.7 
50-54 21.8 18.7 18.0 15.9 3.8 2.8 
55-59 32.1 24.6 25.9 20.1 6.2 4.5 
60-64 44.4 30.7 34.7 24.4 9.8 6.3 
65-69 61.0 39.8 45.6 30.4 15.4 9.4 
70-74 84.2 55.7 58.9 40.3 25.3 15.5 
75-79 119.2 84.0 75.2 56.1 44.0 27.9 
80-84 171.2 129.1 90.9 75.7 80.2 53.5 
85+ 281.2 254.1 110.3 117.2 170.9 136.9 
* Aggregated into five years age classes 
 
Adapted from data source: 
DYNAMO-HIA project originally based on the General Practice Research Database 
(GPRD) from the UK (www.gprd.com). 
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Abstract  
Objectives: To quantify the relation between severity of COPD as expressed by GOLD 
stage and the annual exacerbation frequency in patients with COPD. 
Methods: We performed a systematic literature review for randomized controlled trials and 
cohort studies reporting the exacerbation frequency in patients receiving usual care or 
placebo. Annual frequencies were determined for the following outcomes: total 
exacerbations defined by an increase use of health care (event-based), total 
exacerbations defined by an increase of symptoms and severe exacerbations defined by 
a hospitalization. The association between the mean FEV1% predicted of study 
populations and the exacerbation frequencies was estimated using weighted log linear 
regression with random effects. The regression equations were applied to the mean 
FEV1% predicted for each GOLD stage to estimate the frequency per stage.  
Results: 37 unique studies were found with 43 reports of the total exacerbation frequency 
(event-based: 19, symptom-based: 24) and 14 reports of the frequency of severe 
exacerbations. Annual event-based exacerbation frequencies per GOLD stage were 
estimated at 0.82 (95%CI:0.46-1.49) for mild, 1.17 (0.93-1.50) for moderate, 1.61 (1.51-
1.74) for severe and 2.10 (1.51-2.94) for very severe COPD. Annual symptom-based 
frequencies were 1.15 (95%CI:0.67-2.07), 1.44 (1.14-1.87), 1.76 (1.70-1.88) and 2.09 
(1.57-2.82), respectively. For severe exacerbations, annual frequencies were 0.11 
(95%CI:0.02-0.56), 0.16 (0.07-0.33), 0.22 (0.20-0.23) and 0.28 (0.14-0.63), respectively. 
Study duration or type of study (cohort versus trial) did not significantly affect the 
outcomes. 
Conclusions: This study provides an estimate of the exacerbation frequency per GOLD 
stage, which can be used for health economic and modeling purposes. 
 
Key words: COPD, exacerbations, disease severity, GOLD, review, regression  
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Introduction: 
The progression of chronic obstructive pulmonary disease (COPD) is often accompanied 
by periods of increasing symptoms, such as dyspnea, cough and sputum production, 
named exacerbations. Exacerbations are associated with an increase in mortality (1, 2) 
and have a high impact on health-related quality of life as the number and severity of 
exacerbations impairs the health status of a patient significantly (3-5). Exacerbations are 
also associated with an increase in healthcare use and associated costs (6, 7), especially 
in case of a hospitalization (8). Exacerbation frequency is therefore an important outcome 
parameter for patients with COPD (9, 10).  
Quantification of the average exacerbation frequency however, is difficult. Many studies 
report the exacerbation frequency but results can not be compared directly as different 
definitions are used, exacerbations are measured in different seasons (9) or data come 
from different types of studies, e.g. clinical trials or cohort studies, each using specific 
inclusion criteria (10).  Especially the use of different definitions seems to have a large 
influence. These definitions can roughly be divided in two groups: the symptom-based 
definitions and the event-based definitions. Studies defining exacerbations as self-
reported changes in symptoms (symptom-based definition) generally result in higher 
estimates than studies using event-based definitions, since the estimates also include the 
exacerbations which are not presented to physicians (11). When symptoms are closely 
monitored using diaries, these “unreported” exacerbations are thought to account for 
about 50% of all exacerbations (4). Event-based definitions use more objective criteria, 
such as doctor’s visit, the use of antibiotics and/or systemic steroids or hospitalization. 
However, event-based definitions are sensitive to differences in treatment patterns 
between settings. Besides the different criteria used to define an exacerbation, there is 
also no general agreement on how to classify the severity of an exacerbation. Most 
studies classify exacerbations based on the treatment required, increase of regular 
medication, additional antibiotics and/or systemic corticosteroids or hospitalization (12). 
Despite the difficulties in measuring exacerbations, the general pattern is that the 
frequency of exacerbations increases with decreasing lung function (9, 10, 13). However, 
as far as we know no studies quantified this relationship. The present study aimed to 
quantify the relationship between the degree of airflow obstruction expressed as the 
FEV1% predicted, and the annual exacerbation frequency, using previously published 
data. The association was estimated separately for the two most important types of 
definitions used, symptom-based and event-based and for total and severe exacerbations. 
We also explored the impact of study duration and type of study, i.e. clinical trial or cohort 
study, on this relationship. This study arose out of the need to estimate the average 
exacerbation frequency for the different COPD severity stages as defined by GOLD that 
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were used as input parameters in a dynamic multistate, life table model (14, 15). As this 
model aims to simulate the long-term cost-effectiveness of interventions which 
successfully prevent exacerbations, the exacerbation frequency in patients receiving care 
as usual was essential.   
 
 
Methods 
A systematic literature review was performed for randomized controlled trials and cohort 
studies reporting the exacerbation frequency in patients receiving care as usual or 
placebo. MEDLINE, EMBASE and the Cochrane database were searched using the key 
words “chronic obstructive pulmonary disease” or COPD or “chronic bronchitis” in 
combination with exacerbat* and the specification “cohort or survey or observation* or the 
selection ”clinical trial”. Studies were included if they 1) were published after 1990, 2) had 
a follow-up of at least three months, 3) used an event- or symptom-based definition for an 
exacerbation and 4) included a group of patients that received either usual care or 
placebo (e.g. the placebo arm of a long-acting bronchodilator trial or a combination 
treatment trial). Studies that included a subgroup of COPD patients selected based on 
other criteria than lung function were excluded (e.g. studies only including patients 
admitted to hospital, studies on patients with an acute exacerbation at baseline). 
Retrospective studies based on administrative or claims data were excluded because the 
algorithms to identify exacerbations in these databases are often quite different from the 
definitions used in prospective cohort studies or clinical trials.  Finally cross-references of 
the studies that met the in- and exclusion criteria were checked.  
 
Primary outcomes  
The three main outcomes of the study were the annual frequency of total exacerbations 
using an event-based definition, the annual frequency of total exacerbations using a 
symptom-based definition and the annual frequency of severe exacerbations as defined 
by a hospitalization. One study could provide more than one estimate of the exacerbation 
frequency by presenting separate rates for total and severe exacerbations or rates based 
on both a symptom- and an event-based definition or by presenting rates by GOLD stage.  
 
Data extraction  
Because the comparator arm in our model needs to reflect minimal care, we only 
extracted exacerbation data of the groups of patients that received either usual care or 
placebo. The following data were extracted: percentage males, mean age, and mean lung 
function in FEV1% predicted of the study population, follow-up time, definition of 
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exacerbation used (symptom- or event-based) and the annual exacerbation frequency. If 
the mean FEV1 was only given in liters, the mean FEV1% predicted of the study 
population was calculated based on other studies reporting both liters and percentages 
predicted. If the exacerbation frequency was presented for different classes of the FEV1% 
predicted and the within-class mean FEV1% predicted was not specified, the mean 
FEV1% predicted was estimated based on the mean and the standard deviation of the 
FEV1% predicted in the total population or it was assumed to be the middle FEV1% 
predicted of that specific class.   
Data on the exacerbation frequency were recalculated to annual exacerbation rates, if 
necessary. The annual exacerbation rate was calculated by dividing the total number of 
exacerbations by the total number of patient years using the assumption that drop-outs 
count for half of the follow-up time.  
 
Data analysis 
As almost all studies only provided point estimates of exacerbation rates, uncertainty 
around the exacerbation rates was estimated assuming the exacerbations being Poisson 
distributed within each study. To quantify the relationship between the FEV1% predicted 
and the annual exacerbation frequency, log linear random effect regression analysis was 
performed using the logarithm of the annual exacerbation frequency as dependent 
variable and the mean FEV1% predicted of the study as independent variable. This 
regression analysis was performed using the S-plus routine glm for mixed-effects models 
(16). Analyses were performed separately for total event-based, total symptom-based and 
severe exacerbations. Retransformation of the logarithm of the exacerbations rates to 
exacerbation rates was performed using a smearing factor, which was calculated using 
the model fit residuals following the method of Duan et al (17, 18):  
 
Smearing factor φ= 1/n Σ1-n exp[exacerbationrate_observed - 
exacerbationrate_predicted]  
 
where n was the number of data points in the regression analysis. The relationship 
between the annual exacerbation frequency and the FEV1% predicted was then: 
 
Annual exacerbation frequency = φ * exp[ a+b* FEV1% predicted] 
φ = smearing factor 
a = intercept (estimated in the regression analysis) 
b= coefficient for FEV1% predicted (estimated in the regression analysis) 
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This equation was used to calculate the annual exacerbation frequency in the four COPD 
severity stages according to the GOLD classification (19) using a mean FEV1% predicted 
of 90 for mild, 65 for moderate, 42 for severe and 23 for very severe COPD (20). 
Uncertainty around the exacerbation rates per GOLD stage was estimated by Monte Carlo 
simulation. That is, 1000 random draws were taken from the distribution of the intercept 
and the coefficient for FEV1% predicted. Covariance between the two parameters was 
taken into account by drawing random values for the coefficient for FEV1% predicted that 
were dependent on the values drawn for the intercept. For each combination of intercept 
and coefficient the accompanying smearing factor was calculated using the formula 
described above. The mean FEV1% predicted per GOLD stage was then applied to each 
of the 1000 combinations of intercept, coefficient for FEV1% predicted and smearing 
factor, resulting in 1000 estimates of the exacerbation rate per GOLD stage. The 2.5% 
and 97.5% percentiles of these 1000 estimates formed the 95% uncertainty interval.  
Additional regression analyses were performed adding follow-up time (in months) and 
type of study (cohort versus trial) to FEV1% predicted as dependent variables. The 
analyses were performed with Splus 8.1 (TIBCO Spotfire S+ Version 8.1.1 HF-001 for 
Microsoft Windows, 2008).  
 
 
Results 
The literature review resulted in 86 references of trials and cohort studies published after 
1990 that seemed eligible based on the title. Of these 86 references that were obtained in 
full another 44 studies were excluded because they did not present exacerbation 
frequencies or numbers (n=13), were based on a selective subgroup of COPD patients 
(n=11), were based on a cross-sectional study or on administrative or claims data (n=8), 
had a follow-up less than 3 months (n=9) or used a deviant definition for an exacerbation 
(n=3). The final 42 references referred to 37 unique studies, 28 trials (21-48) and 9 cohort 
studies (3, 6, 49-55). This resulted in 43 estimates for the total exacerbation frequency 
and 14 estimates of the frequency of severe exacerbations. Of the 43 estimates of the 
total exacerbation frequency, 19 used the event-based definition and 24 the symptom-
based definition. Characteristics of all included studies with their annual exacerbation 
rates are presented in Table B1.  
Figure B1 shows the logarithm of the annual total and severe exacerbation frequency 
plotted against the mean FEV1% predicted of the study with the estimated relation 
between the two obtained from the regression analyses. Parameters of the relationship 
between the mean FEV1% predicted of the study and the exacerbation frequency are 
shown in Table B2. Lung function was a predictor of borderline significance for event-
 84
based exacerbations only (p=0.053). Results for the mean exacerbation frequencies for 
the different GOLD stages based on the regression equations are presented in Table B3. 
Using an event-based definition the total exacerbation frequency was significantly higher 
in patients with an FEV1% predicted below 50% compared to patients with an FEV1% 
predicted above 50%. 
Regression analyses with additional covariates showed that in general, no significant 
effect of the duration of follow-up of the study or the type of study (cohort versus trial) was 
found. Only for total exacerbations using the symptom-based definition the duration of 
follow-up was of borderline significance with longer follow-up resulting in lower rates 
(Table B4).  
 
 
Discussion 
Although many trials and cohort studies report on the important outcome, exacerbation 
frequency, the association between lung function and exacerbation frequency is less often 
investigated. The current study gathered the information contained in the literature and 
combined it to an estimate of exacerbation frequency as a function of the FEV1% 
predicted. The final estimates of the total exacerbation frequency per GOLD severity 
stage using the event-based definition were 0.82 for mild, 1.17 for moderate, 1.61 for 
severe and 2.10 for very severe COPD. The coefficient for lung function was of borderline 
significance.  
The reason we have not found a strong relation between lung function and exacerbation 
frequency may be that regression on study summary estimates, as we did in this study, 
has substantially less power than regression on patient-level data (56). There is likely to 
be less variation in lung function across studies than in the patient-level data within 
studies. By plotting the mean exacerbation frequency against the mean FEV1% predicted 
of a particular study, the within study variation is not accounted for. The heterogeneity in 
mean lung function between the studies in our review was relatively limited, especially for 
severe exacerbations. The majority of studies had a mean FEV1% predicted between 35 
and 60% and especially studies with a very low (<30%) and a very high mean FEV1% 
predicted (>80%) were scarce or completely lacking.  
In patient-level data the association of a lower FEV1% predicted resulting in higher 
exacerbation frequencies is seen more clearly (6, 13, 54). Patient-level data on the 
exacerbation frequency specified by subgroup of lung function are however limited. The 
cohort study of Andersson et al, which was included in the review, was the only study 
providing estimates for four COPD severity stages, using almost the same cut-off points 
for the stages as the GOLD classification (6). The study used an event-based definition for 
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exacerbations and found an annual exacerbation frequency of 0.67 for mild, 0.70 for 
moderate, 1.06 for severe and 2.56 for very severe COPD, which were lower than our 
estimates, except for very severe COPD. Vestbo et al reported about the exacerbation 
frequencies in several cohort studies and placebo-arms of trials in relation to the FEV1% 
predicted and also found exacerbation frequencies below 1.0, for patients with an FEV1% 
predicted above 50%. The average values for exacerbations for patients with an FEV1% 
predicted between 40 and 50% ranged between 1 and 1.5, which was comparable with 
our results (10). Burge et al showed the number of exacerbations per year in the placebo-
arm of the ISOLDE trial using an event-based definition and specified the frequency for 
three lung function categories: <1.25, 1.25-1.54 and >1.54 liter (about comparable with 
<45%, 44-55% and >55% predicted). Below 45% predicted a mean of 2.6 exacerbations 
was found, while above >55% the average value was about 1.2 (13). From the above 
described studies the general picture seems to be that above 50% predicted the total 
annual exacerbation frequency is around or slightly below 1.0, while below 40-45% 
predicted the exacerbation rate increases significantly, to about 2 or more exacerbations 
per year. The results of our study showed the same picture. 
In accordance with the general finding that using the symptom-based definition results in 
higher estimates of the total exacerbation frequency, we found slightly higher estimates 
for mild, moderate and severe COPD using the symptom-based definition compared to 
the event-based definition. However, this difference was not significant and seemed to get 
smaller with increasing severity of COPD.  
We also did not see an effect of follow-up time. The mean follow-up in the studies in the 
review was 14 months, ranging from 3 to 36 months. Exacerbations depend on the 
season and are more likely to occur in the winter (3). According to recommendations 12, 
studies therefore need to have a follow-up of at least twelve months to give reliable 
estimates of the exacerbation frequency. Although we choose for a minimal follow-up of 
three months to have more data points for especially the lowest and highest values of the 
mean FEV1% predicted, the majority of studies, 89%, had a follow-up of at least six 
months and 65% had a follow-up of at least one year. Conversion of exacerbation rates 
from studies with a follow-up less than 12 months to annual rates may however have 
overestimated or underestimated the exacerbation frequency, although we did not find a 
significant difference between studies with a follow-up shorter and longer than 12 months.  
No systematic difference was found between the cohort studies and trials. This indicates 
that these selected trial populations seemed to be sufficiently representative for the COPD 
population as seen in daily practice with regard to the exacerbation frequency. 
In conclusion, the current study provided a well based estimate for the average relation 
between the annual total and severe exacerbation frequency and FEV1% predicted in 
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COPD. Results were in line with the few studies reporting about this relation in patient-
level data. However, the general assumption that a lower FEV1% predicted is indeed 
associated with a higher annual number of exacerbations was only true for total 
exacerbations using an event-based definition. 
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Figure legends 
 
Figure B1: Logarithm of the annual total or severe exacerbation frequency plotted against 
the mean FEV1% predicted of the study  
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Figure B1: Logarithm of the annual total or severe exacerbation frequency plotted against the 
mean FEV1% predicted of the study  
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Abstract  
Objective of the study was to estimate the case-fatality of a severe exacerbation from long-
term survival data presented in the literature. 
A literature search identified studies reporting at least 1.5 year survival after a severe COPD 
exacerbation resulting in hospitalization. Each study’s survival curve was divided into a 
critical and a stable period. Mortality during the stable period was then estimated by 
extrapolating the survival curve during the stable period back to the time of exacerbation 
onset. Case-fatality was defined as the excess mortality that results from an exacerbation 
and was calculated as 1 minus the (backwardly) extrapolated survival during the stable 
period at the time of exacerbation onset. The 95% confidence intervals of the estimated 
case-fatalities were obtained by bootstrapping. A random effect model was used to combine 
all estimates into in a weighted average with 95%-confidence interval.  
The meta-analysis based on six studies that fulfilled the inclusion criteria resulted in a 
weighted average case-fatality rate of 15.6% (95%CI:10.9%-20.3%), ranging from 11.4% to 
19.0% for the individual studies.  
A severe COPD exacerbation resulting in hospitalization not only results in higher mortality 
risks during hospitalization, but also in the time period after discharge and contributes 
substantially to total COPD mortality.  
 
Word count abstract: 200 
 
Keywords: case-fatality, chronic obstructive pulmonary disease, exacerbation, 
hospitalization, meta-analysis  
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Introduction 
Worldwide, mortality due to COPD is high. According to the WHO, at least 2.7 million deaths 
are due to COPD every year [1]. The 30-year projections from the Global Burden of Disease 
Study show a striking increase in COPD as a cause of death to the third place worldwide in 
2020 [2]. This increase largely results from a worldwide increase in the prevalence of 
smoking - especially in the developing countries and among women - and aging of the 
population. The excess mortality among patients with COPD is high, not only because of the 
presence of COPD but also because of the increased prevalence of other smoking-related 
diseases [3]. 
Many studies have analyzed predictors of mortality in COPD. Among the factors 
independently associated with mortality in COPD are age, lung function (forced expiratory 
volume in 1 second, inspiratory capacity divided by total lung capacity), dyspnea, co-
morbidity, body mass index (BMI), fat-free mass, exercise capacity, PaO2, C-reactive 
protein, the BODE-index, incorporating BMI, airflow obstruction, dyspnea, and exercise 
capacity and the number of previous hospitalizations [4,5].  
Because patients with COPD are often recorded as dying from other causes, it has been 
suggested that all-cause mortality is probably the best mortality measure to use in COPD [5]. 
Nevertheless, it is well known that many patients dying do so during a severe COPD-
exacerbation, when they experience acute respiratory failure [6]. However, there is a relative 
scarcity of knowledge on mortality rates from COPD exacerbations. Unlike in myocardial 
infarction and stroke [7] no estimates of the case-fatality of a COPD exacerbation exist. This 
may be associated with the absence of consensus on the length of the critical period during 
which the mortality risk is increased.  
The most frequently reported outcome of death due to COPD exacerbations is short-term, in-
hospital mortality [8]. Previous studies have estimated in-hospital mortality after 
hospitalization for a COPD exacerbation to range from 2.5% to 14% [9,10]. Mortality among 
patients admitted to intensive care is much higher, i.e. up to 30% [11]. In-hospital mortality is 
insufficient to assess case-fatality for at least two reasons. There is a selection bias towards 
patients with longer hospital stays and it does not incorporate the mortality that occurs after 
hospital discharge but is still attributable to the index exacerbation. Therefore, the present 
study aimed to estimate the case-fatality of a severe COPD exacerbation including the time 
period after hospitalization. This study arose out of our need to capture the impact of 
exacerbations on mortality within the context of a dynamic, multistate, life-table model [12,13] 
used to evaluate the impact of different COPD interventions. To fully simulate the potential 
long-term impact of interventions which successfully prevent or treat exacerbations the 
impact of severe exacerbations on mortality needed to be estimated. As the COPD 
population in the model is specified by age and age is a significant predictor of mortality in 
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COPD [5], we also investigated the association between age and mortality after a severe 
exacerbation.  
 
 
Methods  
We performed a comprehensive literature search in MEDLINE and EMBASE for journal 
articles published after 1990 reporting mortality or survival during and after hospitalization for 
an exacerbation of COPD using the MESH (sub)headings  “chronic obstructive pulmonary 
disease or COPD or chronic bronchitis” in combination with “mortality or dead or death* or 
life expectancy or survival or prognosis” and “hospital* or admission* or admitt* or 
exacerbation* or disease episodes”. We also searched references listed from articles 
retrieved. Studies were excluded if the patient population was a subgroup of hospitalized 
COPD patients, such as patients requiring mechanical ventilation. Inclusion criteria were: 
European, American or Australian study population; a follow-up period that started at hospital 
entry and lasted at least 1.5 year and presenting mortality rates at three or more time points 
after hospital admission, or presenting a survival curve. Studies that fulfilled all inclusion 
criteria except for a follow-up of 1.5 year or the presence of three data points were used to 
obtain information on the average mortality rates at different time points after a severe 
exacerbation as presented in the literature. In addition to information on the average mortality 
rates at different time points, data on the association between mortality and age was 
extracted from the studies.    
 
Our general approach was as follows (see figure C1). For each study, we extracted the 
presented or estimated survival curve and roughly distinguished between the critical and the 
stable period after hospital admission with the survival curve during the stable period being 
flatter than the one during the critical period. Several data points from the curve during the 
stable period were extracted to estimate survival during this period. Only data points well 
after the critical period were included. For each study, the survival function during the stable 
period was then parameterized using three parameters: 
 
S(t)  = (1-g) Exp[- α t - β t2] 
 
with t time, with t=0 being time of hospital admission 
 S(t) survival probability 
 α, β parameters that define the non-linear change in survival over time 
 g case-fatality of the exacerbation 
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The survival curve was fitted by minimizing the sum of squared differences with the points 
that were extracted from the curve, or given in the publication. Then we extrapolated the 
survival curve during the stable period back to the time of hospital admission and calculated 
where the curve intersected the vertical axis (i.e. the start of hospital admission). The case-
fatality was defined as the excess mortality that results from an exacerbation and equals 
g=1-S(0). Confidence intervals for each parameter were obtained from bootstrapping. 
Conditional on the given initial sample size and the calculated survival probabilities for each 
interval during the follow-up period, we randomly draw new survival numbers assuming 
binomial distributions. In this way we generated new survival curves, resulting in newly 
calculated values for the model parameters. The 2.5% and 97.5% percentile values 
correspond with the 95% uncertainty interval. Finally, estimates from all studies were 
combined to calculate the weighted average for g, using random effect meta-analysis [14]. 
The weights were based on a combination of the sampling error (variance of case-fatality 
within each study) and the random-effect variance (variance of case-fatality between all 
studies).  
To estimate the association between age and mortality after a severe exacerbation, the 
relative risks of age on mortality within a study, if reported, were extracted from the retrieved 
references. The association with age within one study was investigated, as there was little 
difference in the mean age between the different studies. The weighted average relative risk 
was calculated using the variance in the individual studies as a weight.      
 
Results 
After first selection 60 references were obtained in full (see figure C2). Entire review of these 
remaining publications resulted in exclusion of another 44 studies for different reasons (figure 
C2). The main reasons for exclusion were that the association between hospitalization for 
COPD and mortality was not reported (13 studies) and that the study population consisted of 
a selective subgroup of hospitalized patients (13 studies). Of the latter 13 studies, six studies 
included patients admitted to ICU or requiring (non-) mechanical ventilation only, three 
included patients treated in ER or pre-hospital setting only, two included hospitalizations for 
other diagnoses than COPD, while two studies included patients with a first admission or a 
very mild exacerbation only.  
Of the remaining 16 studies, 10 studies met all inclusion criteria except for the 1.5 years of 
follow-up. Hence, a total of six studies were finally included in the meta-analysis to calculate 
the case-fatality rate [15-20]. None of these studies evaluated the effect of an intervention; 
they were all cohort studies. For one of these six studies, the study of Brekke et al [20], we 
had access to the patient level data. For the other five studies results were based on the data 
as presented in the article. Characteristics of the studies included are shown in Table C1.  
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Case-fatality 
Table C2 presents the results of the curve fitting procedure for each of the six studies 
selected. Details about the parameter values for each study are presented in the online data 
supplement. The estimated average case-fatality rate for the individual studies varied 
between 11.4% and 19.0%. The overall weighted mean value of the case-fatality of an 
exacerbation was 15.6% (95% CI: 10.9-20.3%).  
 
Association between mortality and age 
All of the six studies reported about the association between mortality after a hospitalization 
for an exacerbation and age. Age was a significant predictor of mortality in univariate 
analyses (five studies) and remained an independent predictor after correction for other 
explanatory variables in multivariate analyses (4 studies). On average the probability to die 
after a hospitalization for an exacerbation increased with 4.1% per year increase in age 
(RR=1.041 95%CI: 1.037-1.045) (six studies).  
 
Average mortality rates at different time points presented in the literature 
Characteristics of the ten studies with an insufficient length of follow-up are shown in table 
C3 [9,10,21-28]. Table C4 shows the average mortality probabilities at different time points 
for both these ten studies as well as the six studies that were included in the meta-analysis. 
Based on all sixteen studies combined, the weighted mean in-hospital mortality rate was 
4.4%. The average mortality rates at three and six months were 16% and 29%, respectively.  
 
Discussion 
In this study the case-fatality of an exacerbation was calculated by extrapolating the survival 
curve during the stable period to the time of exacerbation onset. The weighted average case-
fatality rate was estimated to be 15.6%, with the individual studies varying from 11.4% to 
19.0%. Comparing our results of the case-fatality with mortality probabilities at specific time 
points (table C4) showed that the weighted average in-hospital mortality rate was 4.4%, 
which strongly supports the notion that the critical period indeed exceeds the duration of the 
hospitalization.  
The exact distinction between the critical and stable period after exacerbation onset 
however, could not be determined. The critical period was defined as the period in which 
mortality is increased compared to the stable situation. This period therefore ranges from the 
hospital admission till the point were the estimated survival curve during the stable period 
approaches the actual observed survival curve (see figure 1). Estimating the point where the 
two survival curves approach each other is only possible if patient-level data are available or 
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when we make additional assumptions on how the case-fatality changes over time within the 
critical period. We had patient-level data of one study, the study of Brekke et al [20]. For this 
study the critical period was estimated to last 4.4 months. The length of the critical period is 
likely to vary according to the population studied; in patients with several co-morbidities the 
exacerbation may have both more severe [9,19] and longer lasting impact and similarly the 
critical period could last longer in the elderly. 
Due to limited data and the homogeneity of the different studies we were not able to specify 
the case-fatality by subgroups such as COPD severity, gender or age. Therefore we 
searched for information about the association of these variables with mortality within the 
extracted studies. Within the studies the relation of mortality due to an exacerbation with 
disease severity or gender was less clear. Mortality after a hospitalization for an exacerbation 
was however highly dependant on age (RR=1.041 per increase in year of age).  
As the study populations of the six studies selected for the meta-analysis were almost the 
same with respect to the mean age, 65 to 71 years, age did no influence the between-study 
comparison of case-fatalities. The studies included have sampled data spanning a time 
period of more than 10 years but no obvious pattern of change over time in case-fatality can 
be seen. This could be the result of the variation in treatment and management between the 
different countries but was actually also seen within one of the included studies [16]. In 
contrast, a very recent study found indications of a slight improvement of exacerbation-
related mortality over time [29]. 
Despite the homogeneity between the studies with respect to age, the study populations may 
have differed on other aspects. Although we selected studies from Western countries, the 
criteria used for hospitalization are for example not similar across countries. This is related to 
local treatment patterns, which in turn may be driven by local guidelines, medical traditions, 
cultural aspects, financing and reimbursement schemes etc. In our selected studies the 
mean length of stay was significantly longer in the European studies compared to studies 
from the USA, 11 versus 7 days. The mean in-hospital mortality rate however, did not differ, 
so possible differences in the characteristics of the study population do not seem to have an 
important effect on the results.  
In conclusion, mortality in COPD is common and severe exacerbations of COPD are one of 
the major causes of death in COPD. In this study the case-fatality rate of a severe 
exacerbation resulting in hospitalization was estimated to be 15.6%, showing the substantial 
impact of exacerbations on mortality.  
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Figure legends 
 
Figure C1: Survival curve after hospitalization for an exacerbation of COPD. The dotted line 
represents the extrapolated curve during the stable phase 
 
Figure C2: Results of the systemic literature search 
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Table C1: Characteristics of studies included in the meta-analysis that aimed to calculate the 
case-fatality of a COPD exacerbation 
1st author of 
the study, year 
of publication 
N Mean  
age 
Patient selection Definition exacerbation Country 
Connors, 1996  1016 70 Patients (age>18yr) with 
clinical diagnosis of COPD 
recorded by a physician 
Hospitalization in combination with 
breathlessness, respiratory failure, 
or change in mental status due 
to COPD as main reason for 
admission and PaCO2<50mmHg 
USA 
Vestbo, 1998  487 67 Patients (age>20yr) admitted 
for COPD (Copenhagen City 
Heart Study) 
Hospitalization (>24 hours) with 
primary diagnosis ICD-8:491-492 
Denmark 
Groenewegen, 
2003  
171 70 Patients with COPD (ATS 
criteria), with a FEV1<70% 
and reversibility<11% who 
were admitted 
Increase of two of three symptoms: 
dyspnea, cough, sputum severe 
enough to warrant hospitalization 
Netherlands 
Gunen, 2005  205 65 Patients with COPD (ATS 
criteria) who were admitted 
Hospitalization for severe increase 
of symptoms (cough, purulent 
sputum and dyspnea), cyanosis 
and oedema, confusion, lethargy, 
coma, use of accessory muscles 
for ventilation, treatment failure, 
acidosis, hypoxemia and/or 
hypercapnia or new arrhythmias 
Turkey 
McGhan, 2007  54269 69 Patients admitted for COPD Hospitalization with primary 
diagnosis ICD-9: 490-492 or 
496 or diagnosis related group 
code of COPD with a primary or 
secondary discharge diagnosis of 
COPD 
USA 
Brekke, 2008  996 71 Patients (age>40 yr) admitted 
for COPD 
Hospitalization with primary 
discharge diagnosis ICD-10:J44.0, 
J44.1, J44.x with J13-J18.9 
Norway 
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Table C2: Estimated case-fatality of a COPD exacerbation 
1st author of the study, 
year of publication 
N Estimated mean 
case-fatality (95% confidence limits) 
Connors, 1996  1016 17.2% (11.5-23.1%) 
Vestbo, 1998   487 12.3% (5.8-18.4%) 
Groenewegen, 2003  171 17.7% (10.2-25.8%) 
Gunen, 2005  205 16.7% (7.9-25.4%) 
McGhan, 2007  53,249 11.4% (10.6-12.2%) 
Brekke, 2008  996 19.0% (18.7-19.3%)# 
   
Overall estimate*  15.6% (10.9-20.3%) 
# Based on patient-level data 
*Overall weighted average case-fatality based on random effects analysis.  
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Table C3: Characteristics of studies with a follow-up less than 1.5 years, excluded from the 
meta-analysis used to obtain information on mortality rates at different time points after a 
severe exacerbation as presented in the literature 
1st author of 
the study, year 
of publication 
N Mean 
age 
Patient selection Definition exacerbation Country 
Fuso, 1995  590 68 Patients with COPD (ATS 
criteria) who were admitted 
Increased dyspnea, reduced 
usual performance with or 
without change in sputum, blood 
temperature and body weight 
less than 5 days prior to 
hospitalization 
Italy 
Cydulka, 1997  131974 75 Patients (age>65yr) 
admitted for COPD 
 
Hospitalization with first 
diagnosis ICD-9: 490-492, 496 
 
USA 
Eriksen, 2003  300 71 Patients admitted for 
COPD 
Hospitalization for COPD 
exacerbation 
Denmark 
Patil, 2003  71130 70 Patients (age>40 yr) 
admitted for COPD 
Hospitalization with discharge 
code ICD-9: 491.21 
USA 
Yohannes, 2005  104 73 Patients (age >60yr)  
admitted for COPD 
Hospitalization for exacerbation 
defined as: presence of  ≥2 
symptoms: increased sputum 
purulence or volume, 
dyspnea, wheeze, chest 
tightness, or fluid retention 
UK 
Wang, 2005  282 71 Patients (>40yr), 
smoker/former smoker, 
FEV1<80%, 
FEV1/FVC<70%, no other 
lung disease who were 
admitted 
Hospital admission for an 
acute exacerbation of COPD 
Canada 
Price, 2006  7529 Unknown Patients with physician-
diagnosed COPD who 
were admitted 
Acute hospital admission for 
COPD 
UK 
Bustamente, 
2007  
763 76 Patients (age>45yr) with 
COPD according to GOLD 
who were admitted 
Hospitalization with diagnosis: 
ICD-9: 491.21 
 
Spain 
 
Kinnunen, 2007  72896# 72 Patients (age>44yr) 
admitted for COPD 
Hospital admission with primary 
diagnosis ICD-8,9: 491, 942, 496 
ICD-10: J41, 42, 43, 44 
Finland 
Dransfield, 2008  825 66 Patients admitted for 
COPD 
Hospitalization with primary 
discharge code ICD-9: 491.21 or 
primary diagnosis of respiratory 
failure 518.81 with second. 
diagnosis COPD exacerbation 
USA 
# Number of admissions instead of number of patients 
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Table C4: Mortality rates after hospitalization for a COPD exacerbation at different time points 
for the seven studies included and the ten studies excluded from the meta-analysis fulfilling 
all inclusion criteria except for a follow-up more than 1.5 years. 
  Mortality rate  
 N In-hospital 3 months 6 months 1 year 2 year 5 year 
Studies included in the meta-analysis     
Connors, 1996  1016 11% - 33% 43% 49% - 
Vestbo, 1998   487 - - - - - 44% 
Groenewegen, 2003  171 8% 16% 18% 23% - - 
Gunen, 2005  205 8.3% - 24% 33% 39% - 
McGhan, 2007  54269 3.6% - - - - 57% 
Brekke, 2008  897 9.9% 22% 27% 32% 41% - 
        
Studies (follow-up<1.5 years) excluded from the meta-analysis    
Fuso, 1995  590 14% - - - - - 
Cydulka*, 1997  131974 6% - - - - - 
Eriksen, 2003   300 8.6% 19% - 36% - - 
Patil, 2003  71130 2.5% - - - - - 
Yohannes, 2005 104 3.8% - - 38% - - 
Wang, 2005  282 9.9% - - - - - 
Price, 2006  7529 7.4% 15% - - - - 
Bustamente, 2007  763 6.4% - - - - - 
Kinnunen, 2007 72896# 3.2% - - - - - 
Dransfield, 2008  825 5.2% - - - - - 
        
Weighted average rate based 
on all 16 studies 
4.4% 16% 29% 36% 44% 57% 
* Results year 1991 
# Number of admissions instead of number of patients  
- Not reported 
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Figure C1: Survival curve after hospitalization for an exacerbation of COPD. The dotted line 
represents the extrapolated curve during the stable phase. 
 
 
 
 
‘case 
fatality’ 
Critical 
phase 
Stable 
phase 
1 
Time 
0 
Survival 
 113 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C2: Results of the systematic literature search 
Total references identified 
n=148 
 
Unique references 
identified n=96 
 
Total references studied 
n=60 
 
 
References rejected based on: 
- Title review: not relevant (n=24) 
- Country of the study population (n=12) 
(not European, American or Australian) 
Studies included in the 
meta-analysis n=6 
 
References rejected based on: 
- Not reporting the association between hospitalization 
for COPD and mortality (n=13) 
- Exclusion of patients dying during the hospitalization 
(n=8) 
- Patient population was subgroup of all hospitalized 
COPD patients (n=13) 
- Same study population already included in the meta-
analysis (n=10) 
Relevant studies 
identified n=16 
Studies which follow-up was too short to estimate the 
case-fatality that were used to obtain information on 
mortality rates at different time points after a severe 
exacerbation as presented in the literature  (n=10) 
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ONLINE DATA SUPPLEMENT 
 
of manuscript  
 
Case-fatality of COPD exacerbations: a meta-analysis and statistical  
modeling approach 
 
 
The survival function during the stable period for each study was parameterized using three 
parameters: 
 
S(t)  = (1-g) Exp[- α t - β t2] 
 
with t time, with x=0 being time of onset of exacerbation 
 S(t) survival probability 
 α, β parameters that define the non-linear change over time 
 g case-fatality of an exacerbation 
 
Table Suppl. C1: Median parameter values (95% uncertainty interval) of the survival function  
1st author of the study, 
year of publication 
α β g 
Connors, 1996  0.482 (0.353-0.608) -0.117 (-0.164 - -0.071) 0.174 (0.115-0.231) 
Vestbo, 1998  0.132 (0.055-0.204) 0.001 (-0.013-0.018) 0.126 (0.058-0.184) 
Groenewegen, 2003  -0.006 (-0.087-0.069) 0.016 (0-0.033) 0.179 (0.102-0.258) 
Gunen, 2005  0.135 (0.058-0.228) -0.014 (-0.03-0.002) 0.17 (0.079-0.254) 
McGhan, 2007  0.229 (0.22-0.238) -0.01 (-0.012- - 0.008) 0.114 (0.106-0.122) 
Brekke, 2008# 0.191 (0.187-0.195) -0.017 (-0.018- -0.016) 0.190 (0.187-0.193) 
# Based on patient-level data 
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APPENDIX D: Mathematical description of the COPD model with exacerbations 
D1. Introduction 
This appendix contains a formal, mathematical description of the COPD model, in addition to 
the short verbal description in section 2.1. An earlier version of the model has been published 
[1]. However, for the sake of clarity the current appendix describes the entire new model. 
After this introduction, the appendix contains three sections. The first presents the general 
formal model structure. The formulas given summarize the Mathematica code that forms the 
model used in the calculations. The model will be described as a deterministic model first, 
followed by a description of how probabilistic sensitivity analysis of model results can be 
performed by taking random draws for a range of parameters values. The section starts with 
an overview of the symbols used throughout this whole section.  
In the second section, for specific elements in the model, the approach taken is further 
elaborated and mathematical background for the equations used is given.  
Finally a third section contains a description of the methods used to find the input values for 
COPD excess mortality.  
 
D2. Description of the general model structure. 
 
D2.1 Overview of symbols used in appendix D2 
Tables D1 to D3 list the symbols used in the current section and the corresponding variable 
name in the MMA code. 
 
Table D1: Definition of index-symbols used in model formulas 
a  age 
r,r’  indexes over smoking classes, r=1,2,3 (never, current, former smoker) 
c index over COPD severity classes, c=1 (no COPD), 2,3,4,5,6 (very severe, 
severe, moderate B, moderate A and mild COPD) 
D, D  with (= conditional on having) and without (= conditional on not having) COPD 
respectively 
a(t)  age on time t  
x  value of continuous lung function 
E  exacerbation (as an event) 
j  Index indicating a decrease (1), or increase in lung function (2)   
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Table D2: Definition of model input parameters, for values see appendix A. 
Category  Symbol MMA code variable 
names 
Explanation 
general 
demography 
mtot(a) morttot All cause mortality 
 
P(a) npop0 Population size 
smoking     P(r;a) prisk1 Initial proportion in smoking class r at age 
a.  
 ))(;(1 tarR+λ  transriskscen transition rate from smoking class r to class 
r+1 (that is: start rate, quit rate or zero) 
 ))(;(1 tarR−λ  transriskscen transition rate from smoking class r to class 
r-1 (that is: zero, zero, or relapse rate)  
COPD: P(D;a) COPDprev Probability of having COPD at age a 
 
em(D;a) COPDexcessmort COPD excess mortality  
 
iD(a) COPDinc COPD incidence rates 
 
Pinc(c|D;a)  initial distribution over severity classes for 
new COPD patients 
 
Pprev(c|D;a)  initial distribution over severity classes for 
current COPD patients 
exacerbations: P(E;x) Makeprobexacerbsev, 
resp 
Makeprobexacerbtot 
exacerbation frequency that depends on 
lung function x 
 
m(E;a) mortexacerb case fatality of a severe exacerbation at 
age a. 
 
FE FEV1exacerb Lung function decrease as a result of a 
severe exacerbation 
smoking and 
COPD: 
);|( aDrP  prokenCOPD0 Percentage of never, current and former 
smokers, conditional on having COPD 
 );|( aDrP  prokennonCOPD0 idem conditional on not having COPD 
 
   
 );,( aDrP   initial joint probability for smoking class r 
and being COPD-free 
risk ratios:    
 )(aRREtot   case fatality relative risk for an 
exacerbation 
 )(xRR Ftot  RRFEVtot/HRFEV
  
all-cause mortality relative risk for lung 
function x 
  
RRrisk  relative COPD risk for smoking class r 
lung function: x’(r,x;t) dFEVdown  autonomous decrease 
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dFEVup increase as a result of smoking cessation 
 
µF(c) meanFEV0 mean lung function values 
 P(E|x), Pall(E|x)  annual probability of a severe or any 
exacerbation respectively(1) 
 fsev(x)  proportion of exacerbations that is 
severe(1) 
 fmod(x)  idem, moderate 
Costs );(
,
acK sevexacerb  costsexacerbsev costs related to severe exacerbations 
 );(mod, acK exacerb  costsexacerbmod costs related to moderate exacerbations  
 );( acKCOPD  costsCOPDpatient maintenance costs for COPD patients 
Health benefits  QALYCOPD(c;a) QALYCOPD  QALY weight related to COPDstage 
 
QALYexaxc,sev QALYexacerbsev  loss of QALY weight because of severe 
exacerbation, as a factor relative to QALY-
weight for COPD severity class 
 
QALYexaxc,mod QALYexacerbmod Idem for moderate exacerbation 
(1) we distinguished moderate and severe exacerbations, and both combined. Only severe exacerbations result in 
increased mortality risks, all exacerbations combined result in lung function decrease, and both have different 
costs. As a result we have the relation P(E|x) = Pall(E|x) fsev(x). 
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Table D3: Definition of model variables, values determined during model initialization or 
model simulation 
Category  Symbol MMA code variable 
names 
Explanation 
general 
demography 
P(S;t)  survival probability 
 moth(a) mortothCOPD other causes mortality rate 
smoking    P(r|S;t)  smoking class r probability value on time t, 
conditional on survival 
COPD: am(D;a) COPDexcessmortadj COPD attributable mortality 
 
iD0(a)  incCOPDbase  baseline COPD incidence rate, that is, 
incidence rate for a never smoking COPD 
free individual 
 );,(1 trcD+λ  ptransCOPDup transition rate to less severe GOLD stage (from c to c+1)  
 );,(1 trcD−λ  ptransCOPDdown transition to more severe GOLD stage (from c to c-1) 
 emoth(c;a) mortnonexacerb excess mortality rate that cannot be 
attributed to exacerbation 
smoking and 
COPD: 
P(r,c;t) nrokenCOPD, 
nrokenCOPD1 
joint distribution function over smoking 
class r and COPD stage c 
 P(r,c;a)  joint probability for smoking class r and 
COPD severity class c 
risk ratios: );( arRM Roth  RMothriskCOPD calculated other causes mortality risk 
multiplier for smoking class r 
 );( arRR Roth    Idem Relative risk 
lung function: x’(r,x;t) dFEVdown  autonomous decrease 
  
dFEVup increase as a result of smoking cessation 
 
f(r,x;t); α,β distFEV, distFEV1, 
distFEV2, distFEV3 
new distribution functions of lung function 
as a result of different events, coefficients 
of the distribution function  
 
µF(r,c;t) meanFEV mean lung function values 
 
f(r,x;t) distFEV, joint distribution function of lung function 
and smoking 
 
f(x|r,c;t)  distribution function of lung function within 
(= conditional on) smoking class r and 
COPD severity class c 
Costs Ktotyr(t)  calculated expected costs for year t 
Health benefits  QALYtotyr(t)  calculated QALYs for year t 
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D2.2 Introduction to model structure.  
The model describes the life course of any individual in terms of changes of smoking class, 
COPD severity class, and lung function value. It is mathematically built in the form of a 
Markov-type state-transition model. Difference equations describe the change of the state 
variables over time, as a result of transitions from one state to the other. The cycle length is 
one year. The two most important state variables in the COPD model are: 1) probability 
values per COPD severity stage (this includes not having COPD as a special stage), per 
smoking class, per age class, and gender, and 2) coefficients characterizing the distribution 
of FEV1%pred within each COPD severity stage per smoking class. The latter distribution 
has to be interpreted as the mean distribution over both genders and all ages. Finally, the 
number of exacerbations in each COPD severity stage is important. 
Basically the model describes how these variables evolve over time and how they are related. 
For instance, the number of current smokers with mild COPD in year t+1 is defined by the 
number of current smokers with mild COPD in year t, adding new mild COPD incidence 
among smokers, adding new as well as restarted ex-smokers among mild COPD patients, 
subtracting smoking cessation in mild COPD patients, subtracting decrease in health status 
to moderate COPD and correcting for mortality. To each state the model attaches estimates 
of annual costs and a quality of life weight.  
Exacerbations are considered as events, not as specific states. In each COPD state, the total 
number of exacerbations per year is estimated, as well as the number of severe and 
moderate exacerbations. These numbers affect several transition rates (mortality, and lung 
function decline) and state specific costs and quality of life.  
Lung function is modeled as a continuous variable. A normal distribution function over the 
entire FEV1% range was used as input and approximated by a linear function within each 
severity class, characterized by two parameters. These parameters change as a result of 
transitions between COPD states, smoking classes, and mortality. In this way, the 
parameters of the distribution function within each severity class also have the Markov-
property: annual changes do not depend on past values, conditional on the current values. 
Almost all model variables are specific to age and gender. To increase the stability of the 
model, a few variables were defined as being constant over gender and age. This refers to 
the parameters of the linear distribution functions of the lung function, and the resulting mean 
lung function values for each COPD severity class. 
Important other smoking-related chronic diseases were included in the model, namely 
myocardial infarction (AMI), stroke (CVA) and lung cancer (LC).  
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This section follows the computational order in the model-code. First all input parameters are 
defined or read from data files and some help variables are computed. The following model 
parameters are calculated based on input data: mortality rates from other causes than COPD, 
case fatality of an exacerbation, the remaining COPD related mortality rates, and the COPD 
incidence rates. Values of the model variables for the start year are defined. These include 
the initial joint probability values for all smoking and COPD severity classes and the initial 
values of parameters of linear distribution function of lung function within each COPD severity 
class.  
Second, for each year in the simulation, three calculation steps are set.  
The 1st step is the calculation of the transition numbers between the smoking classes and 
COPD severity stages. The smoking class transition rates are model input. The COPD 
severity class transition rates are calculated based on lung function decrease and increase, 
the distribution of FEV1%pred in each COPD stage and the number of exacerbations in each 
state.  
The 2nd step is the calculation of new COPD and smoking prevalence probabilities using 
these transition rates and accounting for mortality. Mortality may be due to several causes: 
case fatality of exacerbations, remaining COPD-related mortality, and other causes of death.  
The 3rd step is the calculation of the new FEV1%pred distributions in each COPD stage 
using lung function decrease and increase. The effect of exacerbations was included in the 
decrease and increase of lung function.  
 
 
D2.3 Initialisation.  
The model initialization part consists of calculating all transition rate vales (including mortality 
and incidence) and the initial joint probability values for all smoking and COPD severity 
classes, for both genders and all ages. Moreover, the lung function distribution within each 
COPD severity class is initialized.  
 
a. Prevalence of smoking and COPD severity in base year:  
Initial values of the joint probability of all smoking and COPD severity classes were calculated 
in two steps.  
First, the initial smoking class probability values were calculated conditional on having COPD. 
The relative risk values used to estimate smoking class specific COPD incidence numbers 
were assumed to approximate the relative risk of smoking class for prevalent COPD cases for 
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the start year. The initial smoking class probability value conditional on not having COPD is 
the complement. 
Hence: Prevalence of smoking classes: 
Conditional on having COPD: );();'();'(
);();|(
'
arP
arParRR
arRR
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r
R
D
R
D
⋅
⋅
=
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Conditional on not having COPD: );(1
);|();();();|(
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aDrP
−
⋅−
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Second, initial joint probability values were derived from the conditional ones. Initial smoking 
class probability values were assumed equal for all COPD severity classes. 
 
Smoking class joint with COPD severity class: );|();|();();,( aDrPaDcPaDPacrP prev ⋅⋅=  
Smoking class joint with not having COPD: ∑−= c acrParPaDrP );,();();,(  
 
 
b. Initial values for distributions of lung function. 
For the start year, the FEV1%pred-distributions within each COPD and smoking class are 
approximated using a distribution over all smoking classes. As a result, for the start year, the 
mean FEV1%pred values within each smoking class are approximated by the mean values 
over all smoking classes, which are given as input variables: 
 
)();;( 0 ctcr FtF µµ ==  
 
c. Baseline incidence rates 
In the model, COPD incidence rates per smoking and severity stage are calculated as a 
baseline rate multiplied by a relative risk. These baseline rates are to be calculated from the 
input data, which give overall incidence rates. The input incidence rates are divided by (1-
prev), because data incidence rates apply to the general population and model incidence 
rates apply to the COPD-free population only. They are moreover divided by 
∑ ⋅r
R
D arParRR );();(  to find the incidence rate for a non smoker. 
Baseline disease incidence rate=  
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d. Baseline mortality rates 
Like the incidence rate, COPD mortality rates per smoking and severity stage are calculated 
as a baseline rate multiplied by a relative risk. To find this baseline rate, first COPD 
attributable mortality has to be derived from the difference in all cause mortality between 
COPD patients and non COPD patients (excess mortality), taking into account the effect of 
smoking on both COPD prevalence and all-cause mortality. Excess mortality for COPD is 
adjusted to find the COPD attributable mortality according to the following formula (for details 
see C3.2):  
 
 ))|((1
)))((())(1();(
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rDPE
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The )))((| tottotDr mrmE −  are estimated by using the relative risks for smoking on all-cause 
mortality and COPD incidence: 
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Likewise we have: 
))((| zDPE DR =  ∑ ⋅⋅
r
DD rPrRMrRM )()()(  
 
Mortality from other causes than COPD is now found by subtracting COPD attributable 
mortality from total mortality: )();()()( aamaDPamam Dtototh ⋅−= . If negative other causes 
mortality rate values result, they are set to value 0.  
 
COPD attributable mortality is then to be divided over severity stages using the relative risk 
for mortality of lung function, the average lung function in each severity stage and the 
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percentage of patients in each stage.  To do so, a baseline value is calculated for persons in 
mild COPD:  
 
∑ ⋅
=
c prevF
F
tot aDcPacRR
aDam
aDam );|());((
);();(0 µ
 
 
This mortality is then to be split into exacerbation related case fatality and a rest term. The 
rest term is estimated after definition of policy scenarios that may affect exacerbation 
frequency in the various COPD stages, but before the simulations. It is found by subtracting 
exacerbation related mortality from severity specific COPD attributable mortality:  
 
);());(|();());(();( 0 aEmacEPaDamacRRacam FFFtototh ⋅−⋅= µµ  
To prevent unrealistic values for specific mortality rates to occur the code contains to external 
limits to the results of this calculation, setting its minimum value to 0 and its maximum value 
to 0.6  
 
 
D2.4 Simulation.  
 
a. Apply the distribution of FEV1%pred on the population numbers in each severity stage and 
smoking class to find the fractions flowing to and from neighboring stages 
The fractions flowing from and to each severity stage as a result of the worsening of lung 
function over time (or the improvement of lung function for recent quitters) are called the 
COPD stage transition rates (transCOPD(j,r,c)). 
These are calculated in the model for each year, using distribution characteristics for the 
distribution of FEV1%pred within each severity stage, the lung function decrease/increase in 
that period and changes in the distribution that result from changes in smoking prevalences. 
The lung function decrease/increase in a period, f(j,r,c,g,a), is defined as a function of lung 
function at the lower respectively upper boundary of each severity stage and was estimated 
based on the Lung Health Study data. From the estimated function, the f(j,r,c,g,a) are 
calculated as a function of age, gender, severity stage (i.e. lung function at the boundary of 
the severity stage) and smoking class. To find the COPD stage transition rates, the following 
steps are taken: 
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First, the mean decrease and increase for each severity and smoking class is found as the 
weighted average over age and gender. Increases are only defined for ex smokers in the 
year of quitting. 
Mf(1,r,c) = Σg,a (f(1,r,c,g,a) N(r,c,g,a)) / Σg,a N(r,c,g,a), c=2,..6;r=1,..3 
And 
Mf(2,3,c)= Σg,a (f(2,3,c,g,a) N(2,c,g,a) transsmok(1,2,g,a)) /Σg,a [N(3,c,g,a) + N(2,c,g,a) 
transsmok(1,2,g,a)] c=2,..6, with Mf(2,r,c)=0; r=1,2 
 
Second, new COPD stage transition fractions are calculated for each smoking and 
severity stage. These depend on the current distribution of lungfunction within the stage 
(distfev), the stage, and the size of the transitions (mean decrease or increase) as follows:  
transdown(distfev, c, down(c,r)) = down / (FEVlength(c)*(1+0.5*down*A) / 
(1+0.5*A*FEVlength(c)) 
transup(distfev, c,up)= up / FEVlength(c)*(1+0.5*B*(Fevlength(c)-0.5 up)) / 
(1+0.5*A*Fevlength(c)) 
With   A=Abs(distfev(1)/distfev(2)+eps)),  
B=distfev(1)/(distfev(2)+eps)  
down(c,r)= P(E;x)*FE-Mf(1,r,c) 
up(c,r)=Mf(2,r,c) 
The transition rates are used in step b of the simulation. The mean decreases are used in 
step c of the simulation. 
    
b. Find new prevalences, i.e. new joint COPD severity and smoking prevalences 
The new smoking and COPD stage prevalences are calculated. This uses the transCOPD 
values from step a as well as the mFEV values. 
Prevalence in each smoking and severity stage changes as a result of 
1. COPD related mortality 
2. Mortality from other causes, dependent on smoking class. 
3. Outflow to next smoking class (i.e. from non to current and from current to former 
smoker) 
4. Outflow to previous smoking class (i.e. from former to current smoker) 
5. Outflow to next, i.e. more severe COPD stage (equals 0 for very severe COPD) 
6. Outflow to previous, i.e. less severe COPD stage (equals 0 for mild COPD) 
7. COPD incidence 
8. Inflow from previous smoking class (i.e. new smokers and new former smokers) 
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9. Inflow from next smoking class (i.e. restarting former smokers) 
10. Inflow from previous, i.e. less severe COPD stage (equals 0 for mild COPD) 
11. Inflow from next, i.e. more severe COPD stage (equals 0 for very severe COPD) 
Because the smoking and COPD severity classes are ordered, only transitions to neighbor 
classes are relevant. Another consequence of the state-transition structure of the model is 
that each transition works as both an outflow and inflow. The only exception is mortality.  
This results in the following formulas for prevalence in the stages without and with COPD 
respectively: 
 
For c=1, i.e  for being COPD-free, transitions1,5,6,10 and 11 are irrelevant, while transition 7 
causes outflow : 
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For c>1, that is for persons with COPD, all transitions are relevant and transition 7 causes 
inflow. Transition no 1 consists of COPD attributable mortality not through exacerbations and 
case fatality from exacerbations. 
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Multiplication with initial population numbers results in current prevalence numbers rather 
than current probabilities. 
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Using the above joint smoking and COPD severity class probability values, other probability 
values may be calculated as follows: 
 
Current smoking class probability values conditional on survival: 
 );(
);,();,();|(
tSP
tcrPtDrP
tSrP c∑
+
=  
with survival probability found as: ∑ ∑+= r cr tcrPtDrPtSP , );,();,();(  
 
c. Calculate new distributions of FEV1%pred and new meanFEV1% pred values specific to 
smoking and severity stage 
The new distributions of the FEV1%pred are calculated from the existing distributions, the 
lung function decrease and increase for each COPD stage and smoking class (Mf(j,r,c)) 
found in part 1, as well as from mortality, specified by age, gender, smoking and COPD 
stage. We described the lung function within each smoking and COPD state, which can be 
interpreted as conditional on the state. Therefore we also have to take account of the state 
(class) transitions. Class transitions result from autonomous (due to aging) and intentional 
(due to smoking cessation) changes of the lung function, COPD incidence, and smoking 
class transitions.  
The sum (integral) of the lung function probability values for each joint smoking and COPD 
severity class must equal the probability value calculated in the previous section. However, 
due to the approximations we had to make this equality does not hold exactly. By assumption 
the new joint smoking and COPD severity class probability values are considered the right 
ones. As a result, a new lung function probability distribution function over the entire lung 
function range and for each smoking class is calculated as the product of the joint smoking 
and COPD class probability value times the distribution function conditional on these classes. 
After each time step the opposite calculation step is made and lung function distribution 
functions are calculated conditional on smoking and COPD class. For reason of model 
robustness the distribution of the lung function was only specified by smoking and COPD 
severity class, not by gender or age.  
 
Consequently, for each one-year time-step the following calculation steps are set: 
 
1. Un-conditioning the lung function probability distribution function  
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The distribution function over the entire lung function range and for each smoking class is 
found by multiplying the class probability value with the conditional distribution function: 
 
);,();,|();,( tcrPtcrxftxrf ⋅=  
 
2a. Finding the mean annual change of the lung function, ignoring effects of smoking 
cessation: 
The annual mean change of the lung function for each smoking and COPD severity class is 
found as the sum of autonomous decrease, first term, and additional decrease as a result of 
exacerbations, second term. ‘Mean’ here refers to averaged over both genders and all ages 
for a given smoking class.  
 x’(r,x;t) – α P(E|x) 
The autonomous decrease was based on a regression formula fit on the Lung Health Study 
data, and the effect of exacerbations was added.  
 
2b. Change of parameters of linear lung function distribution due to autonomous decrease 
and to incidence of newly diagnosed COPD patients: 
The change of the lung function distribution function for each smoking and COPD severity 
class was found given the autonomous lung function decrease calculated above. The 
formulas used are described in more detail in section C3.2d below. The new parameters are 
the result of drawing a new linear distribution function that combines the original linear 
functions and the linear functions for the parts added from a less severe COPD severity 
class. Then the effect of incidence is accounted for as follows. The probability mass related to 
the incidence in the joint smoking class r and COPD class c is the 1-year incidence 
probability times the proportion of new cases in class c: 
.  ))(;|();,())(;())((0 tadcPtDrPtarRRtai incRDD ⋅⋅⋅  
The parameters of the lung function distribution for each class are updated by multiplying this 
probability mass with the parameters of the initial lung function distribution within this class. 
 
2c. Change of lung function probability distribution function due to smoking class transitions: 
Since the lung function distribution functions are specified by smoking class, we also 
calculated the effects of transitions between the smoking classes, using the smoking class 
transition rates );1(1 arR −+λ  and );1(1 arR −+λ  . The calculation method is the same as 
described in 2b. 
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Do[distFEV2[[ri, di]] =  
    distFEV1[[ri, di]] (1 - Plus@@ptrsrokenCOPD[[ri, di]])+ 
     If[(ri == 1), 0, ptrsrokenCOPD[[ri - 1, di, 1]] distFEV1[[ri - 1, di]]] + 
     If[(ri == ncr), 0, ptrsrokenCOPD[[ri + 1, di, 2]] distFEV1[[ri + 1, di]]], 
   {ri, ncr}, {di, nFEV}]; 
 
2d. Change of lung function probability distribution function because of increase due to 
smoking cessation: 
Then we calculated the change of the lung function distribution function due to smoking 
cessation for each COPD severity class. This calculation step is made for the former smokers 
only, and is analogous to step 2c. 
Do[distFEV3[[3, di]] =  
    newdistup[If[(di == 1), 
         {0, 0}, 
         distFEV2[[3, di - 1]]], 
       distFEV2[[3, di]],  
       di, 
       dFEVup[[3, di]], 
       If[(di == 1), 0, 1]], 
   {di, nFEV}]; 
 
2e. Change of lung function probability distribution function due to mortality: 
Mortality rates depend on the lung function, so the annual change of the probability density 
function is not the same over the lung function range. Therefore we calculated the change of 
the parameters of the distribution function, approximating the log-linear mortality function by a 
linear one (see C3). 
prevmean = Plus@@hnrokenCOPD / Plus@@Flatten[hnrokenCOPD]; 
   
emmean  = Plus@@Plus@@Table[COPDexcessmortadj[[g]] * 
Plus@@Plus@@nrokenCOPD[[g, All, 1 + Range[nFEV]]], 
{g, ng}] / 
      Plus@@Flatten[ nrokenCOPD[[All, All, 1 + Range[nFEV]]]]; 
   
mu0   = Exp[HRFEVtot FEVbord[[Range[nFEV]]]] /  
Plus@@(Exp[HRFEVtot meanFEV0] prevmean) emmean; 
 
Do[ distFEV3[[ri, All, 1]] = (1 - mu0) distFEV3[[ri, All, 1]] –  
distFEV3[[ri, All, 2]] mu0 HRFEVtot; 
 distFEV3[[ri, All, 2]] *= (1 - mu0), 
 {ri, ncr}]; 
 
3. Conditioning the lung function probability distribution function: 
This is applying the first calculation step backwards: 
 
 
∫ ∈ +
+
=+
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duturf
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tcrxf
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)1;,()1;,|(  
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The mean FEV values as well as the new normalized distribution functions are used in the 
next simulation step. 
 
 
D2.5 Cost and effect calculations  
All calculated model state (smoking and COPD severity class) and event (exacerbations) 
probability values can be valuated in terms of costs and effects. The expected costs for any 
year t are the sum of the exacerbation related costs and COPD maintenance costs. 
Exacerbation related costs are found as the costs per severe or moderate exacerbation 
multiplied with their model state specific frequencies and the size of each model state and 
summed over all model states (see section 2.6). Maintenance costs are found as the size of 
each model state multiplied by the state specific maintenance costs.  
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Similarly, the expected quality of life for any year t was calculated from state specific base 
utilities and exacerbation related utility losses (see section 2.5). The latter were subtracted for 
each state. 
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Total costs and health benefits are then found by adding costs and benefits over the entire 
time horizon. Future costs and effects are discounted using discount rates.  
Running policy scenarios through the model thus results in net present values of total costs 
over the entire time horizon for the different scenarios. Comparing these values to the values 
for the base case scenario, or for a comparator policy scenario, results in incremental costs 
and incremental health benefits. These were related and presented as cost-effectiveness 
ratios.   
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D2.6 Structure of the probabilistic model  
This section describes how the probabilistic sensitivity analysis was carried out in the model 
and how this was implemented in the model code. Section 4.2 presents the parameters 
included in the PSA. 
The figure below pictures the basic structure for performing Monte Carlo simulations, with 
different values for the model parameters in each run. In a first deterministic run, the model 
applies mean parameter values for all variables (run 1). For all runs to follow random 
parameter values are used. In each run the results of several scenarios can be calculated. 
The results of each run are stored in working memory, and in backing store (MMA file 
"outfileresmodelrun.m"). The results of each new model run overwrite the results of the previous 
run in working memory. In case of multiple runs, at the end the distributions of some model 
output variables are presented. 
 
 
 
 
 
 
 
 
 
 
 
 
 
D2.7 Implementation in Mathematica 
This section is intended as a guide through the software code (obtainable from the authors 
upon request).  
The model is implemented in Mathematica (MMA). The main program is a MMA Notebook 
(NB) that calls on several MMA Packages as depicted below.   
 
run 1 given mean 
parameter 
values 
calculation 
steps output 
run 2 
random 
parameter 
values (given in 
file or 
generated) 
calculation 
steps 
output 
run 3 output 
output combined 
(outfileresmodelrun.m
) 
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The package COPDMain.m contains the routine COPDProgram that runs the program. In 
each run the results of all scenarios are calculated. The results of the current run are stored 
in working memory (MMA variable resultres). All results, including those of the previous runs, 
are stored in backing store (MMA file "outfileresmodelrun.m" ). In case of only one model run 
the results are presented in graphical form by the packages  COPDPresent.m and 
COPDCEA.m.  In case of multiple runs, the distributions of some model output variables are 
presented by the packages COPDPresentAll.m and  COPDCEAAll.m.  
 
The key MMA model characteristics to be selected by the user in the main notebook 
(CZMmodelCOPD5.nb) are: 
nstap  the number of one-year time-steps 
nscen  the number of scenarios 
CZMmodelCOPD5.nb Level 0: main 
program 
Level 1: packages 
in 
sub-directories 
COPDMain COPDOther InputData COPDOutput 
COPDMain.
m 
COPDConstants.m 
COPDImportData.m 
COPDFuncties1.m 
COPDSimulation.m 
COPDPresent.m 
COPDCEA.m 
- FEV1distributions 
in each state 
- casefatality 
- exacerbation 
frequency  
- FEV1changes 
- )(xRR Ftot  
- costs 
- QALY 
outfileresmodelrun.
m 
COPDPresentAll.m 
COPDCEAAll.m 
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nrun the number of runs (run 1 uses the mean parameter values; all other runs 
random values) 
The scenarios are defined in MMA programming statements that are packed in string format. 
At the start of each scenario, the string is evaluated, and so the scenario-specific values of all 
scenario (steering) parameters are assessed. 
 
The MMA variable resultres contains the model results of the current model run, and the 
MMA file  "outfileresmodelrun.m" contains the model results of all model runs. The first 
element of this file is the number of runs, and the next elements are copies of the variable 
resultres. This variable is a list of the following outcome variables: 
1. prevrokenCOPDres, prevalence numbers in model states with the size 
nscen*nrun*ng*nr*nd*nage, ie. Number of scenarios times number of runs (time horizon)  
times 2 (male and female) times number of smoking classes times number of COPD severity 
stages. 
2. incCOPDres, COPD incidence numbers, with the size nscen*nrun*ng*nr*nage, that is only 
specific to smoking class, not to COPD severity stage. 
3. mortrokenCOPDres, mortality numbers in model states with the size nscen*nrun* 
ng*nr*(nd-1)*3*nage. Only COPDmortality in COPD stages. Three different types of mortality 
are distinguished: mortality from other causes than COPD, COPD-attributable mortality other 
than from exacerbations, and COPD-attributable mortality from exacerbations. 
4. incres, incidence numbers for other diseases, with the size nscen*nrun*ndis*ng*nage, with 
ndis the number of other diseases distinguished. 
5. prevres, prevalence numbers for other diseases, with the same size 
6. mortcausres, mortality numbers for other diseases, with the same size 
7. distFEVres, parameters of linear distribution of lung function within COPD severity classes, 
with the size nscen*nrun*nr*nd-1*2, since 2 parameters for each distribution function 
are estimated (a and b) 
8. exacerbres, severe and total exacerbation numbers, with the size nscen*nrun*2*nd-1: 
exacerbation numbers in each COPD severity stage, for severe exacerbations only and for 
total exacerbations.  
9. all kea outcomes.  
{QALYCOPD, QALYexacerbsev, QALYexacerbmod, costsCOPDpatient, costsexacerbsev, 
costsexacerbmod},  
This element of the list is a compound Mathematica list that has 6 fields. The first field has 5 
fields itself, one for each COPD severity stage. The second and third fields are single figures 
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reflecting the relative utility decrement for a severe and a moderate exacerbation, 
respectively. The 4th field is a list of size ng*nd-1*nage, containing costs per patient, specific 
to gender and age and COPD severity stage. The 5th and 6th fields are single figures again.  
 
For model verification and debugging several options are available. In the package 
COPDMain the MMA variable bugind is defined. In case of value 1 labels are printed on 
screen that enables the model user to locate program errors. In case of multiple runs 
(nrun>1), no labels are printed because that would slow down the program too much. In the 
package COPDSimulation.m the MMA variable plotind is defined. In case of value 1 the 
calculated lung function distribution functions are presented graphically.  
The file maakprint.bat generates a listing in ASCII-format of all MMA packages used. 
 
 
D3. Mathematical background for specific model elements. 
This section provides further elaboration on specific model elements. The mathematical 
model was defined in continuous time. We have made this model time-discrete using 1-year 
time-steps using the Euler-method of order 1. In section C2 the description hence was as 
much as possible in terms of 1 year time steps, but this section will describe the original 
mathematical structure in continuous time.  
 
Section C3.1 describes the linear approximation of the distribution function of the lung 
function within each severity class. We work out the formulas for several aspects: the 
calculation of the annual COPD severity class transition probability, the annual update of the 
parameters of the linear distribution function, and the effect of mortality on these parameters.  
Section C3.2 discusses all parameters that are related to mortality. We start in C3.2a with the 
excess mortality rate and adjust to a mortality rate that uniquely can be attributed to COPD. 
The calculation method is part of the standard methodology of the RIVM Chronic Disease 
Model. We proceed in C3.2b with the case fatality of an exacerbation. Then in C3.2c, the 
proportion of the COPD-related excess mortality that does not result from the case fatality of 
exacerbations is found.  Finally mortality from other causes is defined in C3.2d.   
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D3.1   Issues related to lung function 
 
a. The joint distribution over smoking class and lung function 
Essentially, our model describes the joint probability distribution function over smoking and 
lung function of any COPD-patient, and its change over time. Because the lung function is a 
continuous variable and we did not want to fix the form of the lung function distribution 
function, we chose a semi-parametric form. I.e., we distinguished several COPD severity 
classes using lung function cut-off points, and we approximated the distribution function 
within each COPD severity class by a linear function. The result is a so-called non-continuous 
piecewise linear function, with the severity class cut-off points being the break-points. 
 
We start with the general joint probability distribution function over smoking and lung function 
of any COPD-patient. We describe how the value for time t depends on the values for time t-
∆t, for any lung function value f and smoking class r. At first we assume the smoking class r 
being fixed, and thus allow no smoking class transitions, and assume no mortality. The 
mathematics to describe the change over time of the lung function probability distribution 
function is similar to the mathematics of water flows. We have to relate the change of the 
probability distribution function to the change of the lung function itself. We start with any time 
point t, and describe the change of the cumulative probability distribution function as a 
function of the cumulative probability distribution function on time point t-∆t, with ∆t being 
sufficiently small. 
  
 
The mathematical equation that describes the change of the cumulative probability 
distribution function is: 
r,
x 
r,x-x’(r,x;t) ∆t 
t t-∆t 
 136 
txtxrxtxr
x
f
txtxrxtxrfxtxrf
ttxrxtxrf
txtxrxtxrxxtxr
x
f
txrfxtxrf
ttxrxtxrftxrFttxxrxtxxrftxxrF
tttxrxxrFtttxxrxxxrF
txrFtxxrF
∆⋅∆⋅⋅−∆⋅∆⋅⋅−∆⋅
=∆⋅⋅
+∆⋅∆⋅+∆⋅+−∆⋅
=∆⋅+−∆⋅∆+⋅∆+−∆+
=∆⋅−−∆⋅∆+−∆+
=−∆+
);,(');,();,('');,();,(
);,(');,(
]);,('');,('][);,();,([);,(
);,(');,();,();,(');,();,(
););,(',(););,(',(
);,();,(
δ
δ
δ
δ
 
Moreover we find: 
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Combining both equations results in: 
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x, ∆x continuous lung function, small change of lung function respectively 
r smoking class 
t, ∆t time, small time interval respectively 
x’(r,x;t) rate of change of lung function over time 
x”(r,x;t) rate of rate of change of lung function over time 
F(r,x;t) cumulative probability function over lung function x for fixed smoking class r on time t 
f(r,x;t) probability density function over lung function x 
 
The equation we derived is an example of a so-called partial differential equation: it relates 
the changes over both arguments time t and lung function value x. E.g., take the last term of 
the equation: if the lung function increases over time t (x’(r,x;t)>0) and if the probability 
density function increases over lung function value x for fixed time t  ( );,( txr
x
f
δ
δ
>0), then the 
probability density function decreases over time t for fixed lung function value x. 
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This mathematical equation becomes much more complex by introducing transitions between 
smoking classes. A formal analytical solution is far too complex. That’s why we have 
approximated both the solution to the effects of the simultaneous smoking class and lung 
function value changes, and the solution to the time-continuous change of the lung function 
itself (see equation above). This approximation consists of the following successive 
calculation steps, i.e. we calculate how the probability distribution function changes for all 
joint smoking and COPD severity classes: 
1 due to the autonomous time-continuous decrease, including the effect of 
exacerbations and incidence 
2 because of the smoking class transitions using the smoking class transition rates 
3 due to the increase of the lung function because of smoking cessation 
4 due to mortality 
In the 3rd calculation step we again (see step 1) fixed the smoking classes, so the lung 
function effect of smoking cessation is diluted over all former smokers. 
 
b. The piecewise-linear distribution function of the lung function 
 
We approximated the probability distribution of the lung function by a linear function within 
each COPD severity class: 
 xcxf ⋅+= βα)|(  
x continuous lung function; x=0 corresponds with the left cut-off value of the COPD 
severity class 
α intercept  
β regression coefficient 
c index over COPD severity classes 
The parameters α and β also depend on c formally.   
The probability of being in a smoking and COPD severity class is defined elsewhere in the 
model (C2.4c). At the start and end of each one-year time-step we un-condition and condition 
the probability distribution function on the COPD severity class respectively (see also C2.4c). 
The resulting distribution function is called a piecewise-linear function, although the function 
is not continuous in the lung function cut-off points. 
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c. COPD severity class transition probability 
The problem addressed here is: given the linear distribution of the lung function within a 
COPD severity class, and the annual change of the lung function, what is the proportion that 
leaves the state? We distinguish an increase of the lung function that results in a transition to 
the severity class on the right, and a decrease of the lung function that results in a transition 
to the severity class on the left. (See figure x) 
 
 
 
 
β’ transformed regression coefficient, β’= β/α 
D length of COPD severity class 
d annual change of lung function 
x continuous lung function value 
)',,(1 βλ Dd+  annual transition probability due to increase of lung function  
)',,(1 βλ Dd−  idem, due to decrease 
Case of increase of lung function: 
 Probability mass that moves out: )'½'1( dDd ⋅⋅−⋅+⋅⋅ ββα  
 Current probability mass:  )'½1( DD ⋅⋅+⋅⋅ βα  
 Proportion moving out:  
D
dD
D
dDd
⋅⋅+
⋅−⋅+
⋅=+
'½1
)½('1)',,(1 β
ββλ  
Case of decrease of lung function: 
 Probability mass that moves out: )'½1( dd βα +  
 Proportion moving out:  
D
d
D
dDd
⋅⋅+
⋅⋅+
⋅=
−
'½1
'½1)',,(1 β
ββλ  
NB: the severity class transition probability values only depend on β’ = β/α, not on the 
absolute values. The proportions moving out correspond with the model transition 
lung function (x) 
D 
d
>increase 
d
f(x) = α ( 1 + β’ x) 
) 
density function 
< decrease 
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probabilities (increase) );(1 tcD+λ and (decrease) );(1 tcD−λ for any COPD severity class c on 
time t (see C2.4). 
 
 
d. New linear lung function probability distribution 
The problem addressed here is: what is the best approximation of the linear lung function 
distribution function that is constructed from two successive linear distribution functions. We 
distinguish between an increase and decrease of the lung function. 
 
Case of increase of lung function: 
 
 
 
 
 
 
 
 
 
 
 
d lung function values (interval) that crosses the cut-off point on the left 
D lung function values (interval) that stay within class during one year, i.e. do not cross 
the cut-off point on the right during the year 
 
d is the lung function interval in the COPD severity class on the left that crosses the cut-off 
point on the left. The related probability mass describes the transition number. Likewise, D is 
the lung function interval that does not cross the cut-off point on the right. The linear 
distribution function for the part coming from the severity class on the left is f(x) = c1 + d1 x, 
and the one for the part staying in the class is f(x) = c2 + d2 x. The new linear distribution 
function is f(x) = a + b x, and minimizes the following sum of squares (Mathematica format): 
 
f[a_,b_]:= 
Integrate[((a+b x)-(c1 +d1 x))^2,{x,0,d}]+ 
Integrate[(a+b ( x+d)-(c2+d2 x))^2,{x,0,D}] 
 
The solution is found by setting the derivatives of f to parameters a and b to 0. Then: 
a→(c1 d (d+4 D)+D (c2 (-2 d+D)+d (2 d d1-D d2)))/(d+D)2, 
b→(-6 c1 d D+6 c2 d D+d3 d1-3 d2 D d1+3 d D2 d2+D3 d2)/(d+D)3 
lung function (x) 
density function 
D d
f(x) = a+bx 
f(x) = c2+d2x 
f(x) = c1+d1x 
cut-off point 
 
cut-off point 
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Case of decrease of lung function: 
 
 
 
 
 
 
 
 
 
 
d lung function values (interval) that crosses the cut-off point on the right 
D lung function values (interval) that stays within class during one year, i.e. do not cross 
the cut-off point on the left during the year 
 
The linear distribution function for the part coming from the severity class on the right is f(x) = 
c1 + d1 x, and the one for the part staying in the class is f(x) = c2 + d2 x. The new linear 
distribution function is f(x) = a + b x, and minimizes the following sum of squares 
(Mathematica format): 
g[a_,b_]:= 
Integrate[((a+b x)-(c1+ d1 x))^2,{x,0,D}]+ 
Integrate[((a+b (x+D))-(c2+d2 x))^2,{x,0,d}] 
 
The solution is found by setting the derivatives of g to parameters a and b to 0. Then: 
 
a→(c2 d (d-2 D)+D (c1 (4 d+D)+d (2 D d1-d d2)))/(d+D)2, 
b→(-6 c1 d D+6 c2 d D-3 d D2 d1+D3 d1+d3 d2+3 d2 D d2)/(d+D)3 
 
In case of increase of the lung function no inflow into the first (very severe) COPD severity 
class exists, while in case of decrease no inflow into the last (mild) severity class exists. 
Therefore, we introduced a weight parameter w in the two sums of squares defined above. 
Weight w describes the weight of the lung function interval that crosses the cut-off point.  In 
the two cases described above, the weight w has value 0, otherwise value 1. 
 
lung function (x) 
density function 
D d
f(x) = a+bx f(x) = c1+d1x 
f(x) = c2+d2x 
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e. Effect of mortality on linear distribution function 
The mortality rate depends log-linearly on the lung function. We approximated this by a linear 
function: )1()( 00 xmemxm x ⋅+⋅≈⋅= δδ  
m mortality rate 
m0 intercept 
δ regression parameter 
 
Then the new linear lung function distribution function can be approximated by: 
 xmmmxmxcxf ⋅⋅⋅−⋅−+⋅−≈⋅+⋅−⋅⋅+≈ ])1[()1())1(1()()|( 0000 δαβαδβα  
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C3.2   Issues related to mortality  
 
a. Definition of excess mortality and attributable mortality 
The COPD-related excess mortality rates are defined as: );();();( aDmaDmaDem −=  
em(D;a) COPD-related excess mortality 
);( aDm  mortality rate conditional on having COPD 
);( aDm  mortality rate conditional on not having COPD 
That is, it is the additional mortality rate for a person with COPD compared to the rate of a 
person without COPD. These COPD-related excess mortality can be explained by differences 
in mortality rates for all co-morbid diseases that are causally related with COPD or that are 
indirectly related through joint risk factors. Smoking, for instance, is a risk factor for COPD 
mortality. As a result COPD-patients have higher lung cancer mortality risks compared to 
COPD-free persons and so part of the COPD-related excess mortality can be explained by 
lung cancer mortality rates that are different between COPD-patients and COPD-free 
persons.   
 
b. COPD-related excess mortality adjusted for smoking 
The COPD-related excess mortality rate describes the difference between the mortality rate 
of any person with and without disease, i.e. unadjusted for smoking. In the model we need 
the excess mortality rate adjusted for smoking. We call the latter the COPD-related 
attributable mortality rate. We show how the COPD-related attributable mortality rates are 
calculated from the excess mortality rates. All mathematical equations in this section are 
formulated in general terms. For our model disease D has to be read as COPD, and frailty 
variable z has to be read as smoking. The calculation method is based on combining the 
mortality rates in a homogeneous and heterogeneous population, i.e. unadjusted and 
adjusted for smoking respectively. For notational convenience the time parameter was 
omitted here. 
 
Homogeneous population 
mortality among patients = mortality rate conditional on having disease D 
Dtottot emDmDm += )()(       (1) 
mortality in population = unconditional mortality rate 
Dtottot emDPDmm )()( +=       (2) 
=> DtotDtottot emDPmemDmDm ⋅−+=+= ))(1()()(  
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with D  disease index, D : without disease D (= COPD) 
P(D)  disease D prevalence rate = proportion with D 
mtot  all cause mortality rate 
emD  disease D related excess mortality rate 
mtot( D ) mortality rate from other causes of death = mortality of persons without 
disease D = mortality rate conditional on not having disease D 
mtot(D) mortality rate among patients = mortality rate conditional on having 
disease D 
 
Heterogeneous population 
 
For any frailty variable Z (smoking) 
Doctot amZDPZmZm ⋅+= )|()()(  
 
with: Z,z  stochastic frailty variable that describes the population heterogeneity 
mtot(Z),moc(Z) mortality rate for all causes and other causes of death respectively 
amD  disease D related attributable mortality rate 
 
Then: 
Docz
Dtottot
amDzmE
emDPmDm
+=
⋅−+=
))|((
))(1()(
 
 
 
]))(([
))]|((1[
))(1(
)(
|
|
tottotDz
DDz
D
tottot
mzmE
amzDPE
emDP
mDm
−
+⋅−
=⋅−
=−
 
The latter formula results in a formula for calculating the disease related attributable mortality 
rates from the excess mortality rates: 
 
 ))|((1
)))((())(1(
|
|
zDPE
mzmEemDP
am
Dz
tottotDzD
D
−
−−⋅−
=  
 
The all cause mortality rates ))((| zmE totDz  and disease D prevalence rates ))|((| zDPE Dz are 
calculated using relative risk values )(ZRRtot  and )(ZRRd . 
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c. Further specifying COPD-related mortality 
For the model COPD-related attributable mortality was subdivided in mortality that results 
from severe exacerbations (case fatality, see d), and rest attributable mortality (see e). 
 
 
d. Case fatality of severe exacerbation  
We calculated the case fatality of a severe exacerbation, i.e. the attributable mortality risk that 
uniquely can be attributed to a severe exacerbation. The relative risk )(aRREtot describes the 
relative change of the case fatality with age. 
 
Case fatality of exacerbation: );()();( 0aEmaRRaEm Etot ⋅=  
a0  reference age value; a0 = 74 
m(E)  given case fatality of severe exacerbation  
m(E;a)  calculated case fatality of severe exacerbation on age a 
)(aRREtot  relative change of case fatality of severe exacerbation with age; = 1.04 
 
We calculated the reference age value a0 by assuming that the given empirical value m(E) 
equals the mean value over all COPD-patients in our model: 
  
all cause 
mortality 
COPD-related 
attributable  mortality 
mortality from 
other causes 
case fatality 
of severe 
exacerbations 
rest attributable  
mortality 
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157.)();();|());(|(
)();();|());(|();(
,
,
=
⋅⋅⋅
⋅⋅⋅⋅
∑
∑
ca prevF
ca prevF
aPaDPaDcPacEP
aPaDPaDcPacEPaEm
µ
µ
 
 
µF(c;a)  initial mean lung function in COPD severity class c on age a 
P(a)  population frequency according to Statistics Netherlands 
 
e. Rest attributable mortality rate values 
The COPD-related attributable mortality rates are calculated from COPD-related excess 
mortality rates (see section c.). The larger part of these attributable mortality rates can be 
explained by the case fatality of severe exacerbations. The rest is called the rest COPD-
related attributable mortality rates here. Of course, the rest attributable mortality rates 
amoth(c;a) must be non-negative.  
 
Baseline COPD-related attributable mortality rate: 
∑ ⋅
=
c prevF
F
tot aDcPacRR
aDam
aDam );|());((
);();(0 µ
 
 
Rest COPD-related attributable mortality rate, i.e. not through severe exacerbations: 
);());(|();());(();( 0 aEmacEPaDamacRRacam FFFtototh ⋅−⋅= µµ  
f  continuous lung function value 
am0(D;a) baseline COPD-related attributable mortality, i.e. for baseline severity class 
)( fRR Ftot  relative mortality risk for lung function value f 
amoth(c;a) COPD-related attributable mortality for severity class s not through severe 
exacerbations 
P(E|f)  annual probability of severe exacerbation conditional on lung function f
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f. Other causes mortality rate values 
The mortality rate of any person without COPD can be calculated from all cause mortality 
rates, COPD-related excess mortality rates, and COPD prevalence probabilities. It can be 
interpreted as the other causes mortality rate (see b). The other causes mortality rate moth(a) 
must be non-negative. NB: we have distinguished other causes mortality rates moth(a) and 
rest COPD-related attributable mortality rates amoth(c;a) here. The former apply to any person 
and depend on smoking class, the latter apply to COPD-patients only and depend on COPD 
severity class. 
 
Mortality rate from other causes than COPD for any individual: 
)();()();()( aamaDPamaDmam Dtototh ⋅−==  
Other causes mortality rate multiplier for smoking class r: 
)();()(
)();();()();(
)(
);();(
aamaDPam
aamaDParRMamarRM
am
arm
arRM
Dtot
D
R
Dtot
R
tot
oth
othR
oth
⋅−
⋅⋅−⋅
==  
Other causes mortality risk ratio: 
 );1(
);();(
aRM
arRM
arRR R
oth
R
othR
oth =  
mtot(a)  given all cause mortality rates for any individual 
moth(a)  calculated mortality rate from other causes than COPD 
mtot(r;a) all cause mortality rate for smoking class r 
moth(r;a)  other causes mortality rate for smoking class r 
);( arRM Roth   other causes mortality rate multiplier for smoking class r 
);( arRR Roth  other causes mortality risk ratio 
Mortality rate multipliers );( arRM Roth  and mortality rate ratios );( arRR Roth  are similar, but not 
equal. Risk ratios are defined as the ratio of the mortality rate for any smoking class r to the 
one for the reference (non-smoking) class. We assume these risk ratios being constant over 
time, conditional on age. Rate multipliers are defined as the ratio of the mortality rate for any 
smoking class r to the mean population rate value. As a result, they change over time, but the 
weighted sum has always value 1 for any time point t. 
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D4 Data used to find COPD mortality  
The input parameters for unadjusted COPD excess-mortality were taken from the RIVM 
Chronic Disease Model. The following is a short summary description of the COPD specific 
input data. Further details can be found in publications on the RIVM Chronic Disease Model.   
 
Data used are:  
1.  the UK GP registration (DYNAMO-HIA project/GPRD) concerning mortality in COPD and 
non-COPD patients over the period 2000-2008 [2]. The total number of persons in the 
DYNAMO-HIA/GPRD consists of more than 3,5 million and the number of COPD deaths over 
the period 2000-2008 was 37000.   
2.  Dutch GP registrations of COPD incidence and prevalence. [3] 
 
The DYNAMO-HIA/GPRD data were used to estimate a RR for mortality in COPD patients. 
The RR was estimates using Poisson regression, with as explanatory variables polynomials 
of age, COPD status, gender and interaction terms. Using the BIC criterion, the best model 
was selected. Results are presented in figure D4.1 below.  
Figure D4.2 then presents the resulting relative risks and excess mortality rates, if the 
regression model is applied. Confidence intervals were obtained using Monte Carlo 
simulation. 
The RRs were then combined with COPD prevalence estimates based on Dutch GP 
registrations and Dutch overall mortality rates (statistics Netherlands) to find estimates for 
COPD mortality in the Netherlands as follows:  
Othercause_mortalityNL = total_mortalityNL/{ prev COPD NL*RR_DYNAMO-HIA/GPRD+ (1- 
prev OCPD NL)} 
Exces_mortalityNL= { RR_DYNAMO-HIA/GPRD-1}* Othercause_mortalityNL 
 
Figure D4.3 shows the resulting excess mortality rates and life expectancies for men and 
women with COPD.  
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Figure D4.1: Mortality rates in raw DYNAMO-HIA/GPRD data and fitted functions (men and 
women).  
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Figure D4.2 : relative risk for mortality (mortality in  COPD)/(mortality in persons without 
COPD) and excess mortality (motrality with  COPD) -/- (mortality in persons without COPD)   
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Figure D4.3: excess mortality and life expectancy for COPD patients  
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APPENDIX E: Internal validity checks 
 
During the development of the model, the internal validity of the model was secured by 
performing fifteen different model checks to prevent internal inconsistencies. The performed 
model checks, results and possible actions to resolve the problem are shown in the Table 
below.
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de
cli
n
e
 
se
t 
to
 
ze
ro
 
N
o
 
an
n
u
al
 
de
cli
n
e 
in
 
lu
n
g 
fu
n
ct
io
n
,
 
re
su
lts
 
in
 
re
du
ce
d 
di
se
a
se
 
pr
o
gr
e
ss
io
n
,
 
le
ss
 
m
or
ta
lit
y 
an
d 
m
or
e 
(Q
A)
LY
s 
co
m
pa
re
d 
to
 
th
e
 
re
fe
re
n
ce
 
sc
e
n
ar
io
 
a
n
d 
co
m
pa
re
d 
to
 
a
 
sim
ul
at
io
n
 
w
ith
 
a 
fiv
e 
tim
e
s 
hi
gh
er
 
ef
fe
ct
 
on
 
lu
n
g 
fu
n
ct
io
n
.
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s 
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.
 
Ef
fe
ct
 
o
n 
lu
n
g 
fu
n
ct
io
n
 
de
cli
n
e
 
se
t 
fiv
e 
tim
e
s 
hi
gh
er
 
In
cr
ea
se
d 
lu
n
g 
fu
n
ct
io
n 
de
cl
in
e 
re
su
lts
 
in
 
in
cr
e
as
e
d 
di
se
a
se
 
pr
o
gr
es
sio
n
,
 
in
cr
e
a
se
d 
m
or
ta
lit
y 
a
n
d 
le
ss
 
(Q
A)
LY
s 
co
m
pa
re
d 
to
 
th
e
 
re
fe
re
n
ce
 
sc
en
ar
io
 
a
n
d 
co
m
pa
re
d 
to
 
a
 
si
m
ul
at
io
n
 
w
ith
 
th
e 
ef
fe
ct
 
o
n 
lu
n
g 
fu
n
ct
io
n
 
se
t t
o
 
ze
ro
.
 
 
Th
e 
n
um
be
r 
of
 
LY
s 
an
d 
th
e
 
n
um
be
r 
of
 
QA
LY
s 
a
re
 
in
de
e
d 
hi
gh
e
r.
 
M
or
ta
lit
y 
is
 
o
n
ly 
hi
gh
e
r 
in
 
th
e 
fir
st
 
fo
u
r 
ye
ar
s.
 
 
 
12
.
 
Ef
fe
ct
 
o
n 
e
xa
ce
rb
a
tio
n
 
fre
qu
e
n
cy
 
se
t t
o
 
ze
ro
.
 
 
N
o
 
ex
a
ce
rb
at
io
n
s 
re
su
lts
 
in
 
le
ss
 
m
o
rta
lit
y 
an
d 
m
or
e 
(Q
A)
LY
s 
co
m
pa
re
d 
to
 
th
e
 
re
fe
re
n
ce
 
sc
en
ar
io
 
a
n
d 
co
m
pa
re
d 
to
 
a
 
sc
e
n
a
rio
 
w
ith
 
th
e 
th
re
e
 
tim
es
 
hi
gh
e
r 
ex
a
ce
rb
a
tio
n
 
fre
qu
e
n
cy
.
 
 
N
u
m
be
r 
of
 
(Q
A)
LY
s 
is 
in
cr
e
as
ed
,
 
m
or
ta
lit
y 
di
d 
n
ot
 
ch
a
n
ge
.
 
 
Ef
fe
ct
 
o
n
 
e
xa
ce
rb
a
tio
n
 
fre
qu
en
cy
 
w
a
s 
ap
pl
ie
d 
to
 
th
e 
ex
ac
e
rb
at
io
n
 
fre
qu
en
cy
 
af
te
r 
ca
lc
ul
at
in
g 
th
e 
 
ba
se
lin
e 
pa
ra
m
et
er
s 
in
 
 
1s
t  
ye
a
r 
of
 
th
e 
m
od
el
 
# 
13
.
 
Ex
a
ce
rb
a
tio
n
 
fre
qu
e
n
cy
 
th
re
e 
tim
es
 
hi
gh
er
 
th
a
n
 
th
e 
re
fe
re
n
ce
 
sc
en
ar
io
 
M
or
e 
e
xa
ce
rb
at
io
n
s 
re
su
lts
 
in
 
in
cr
e
as
e
d 
m
or
ta
lit
y 
an
d 
le
ss
 
(Q
A)
LY
s 
co
m
pa
re
d 
to
 
th
e
 
re
fe
re
n
ce
 
sc
en
ar
io
 
a
n
d 
co
m
pa
re
d 
to
 
a
 
sc
e
n
a
rio
 
w
ith
 
th
e 
e
xa
ce
rb
at
io
n
 
fre
qu
e
n
cy
 
se
t t
o
 
ze
ro
.
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N
R
 
Ch
ec
k 
Ex
pe
ct
ed
 
o
u
tc
o
m
e 
O
u
tc
o
m
e 
as
 
ex
pe
ct
ed
? 
If 
n
o
, 
w
ha
t i
s 
do
n
e 
to
 
re
so
lv
e 
th
e 
pr
o
bl
em
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Al
l-c
a
u
se
 
m
or
ta
lit
y 
th
re
e 
tim
es
 
hi
gh
er
 
th
a
n
 
th
e 
re
fe
re
n
ce
 
sc
en
ar
io
 
H
ig
he
r 
m
or
ta
lit
y 
a
n
d 
le
ss
 
(Q
A)
LY
s 
co
m
pa
re
d 
to
 
re
fe
re
n
ce
 
sc
e
n
a
rio
 
 
Ye
s 
 
15
.
 
Al
l u
tili
ty
 
va
lu
e
s 
ar
e 
se
t t
o
 
1.
0 
Th
e 
n
u
m
be
r 
of
 
QA
LY
s 
eq
u
al
s 
th
e 
n
u
m
be
r 
of
 
life
 
LY
s 
 
Ye
s 
 
 N
o
te
s:
 
*
Th
e 
n
o
rm
al
 
di
st
rib
u
tio
n
 
of
 
th
e
 
FE
V 1
%
 
pr
e
di
ct
e
d 
of
 
th
e
 
CO
PD
 
po
pu
la
tio
n
 
is
 
tru
n
ca
te
d 
at
 
10
 
an
d 
11
0%
.
 
D
is
e
as
e 
pr
og
re
ss
io
n 
in
 
pa
tie
n
ts
 
w
ith
 
ve
ry
 
se
ve
re
 
CO
PD
 
w
ith
 
a
n
 
FE
V 1
%
 
pr
e
di
ct
ed
 
ar
o
u
n
d 
10
%
 
pr
ed
ic
te
d 
co
u
ld
 
re
su
lt 
in
 
a
 
sm
al
l p
er
ce
n
ta
ge
 
cr
os
sin
g 
th
e 
10
%
-
lin
e.
 
Th
is 
pe
rc
e
nt
ag
e 
of
 
pa
tie
n
ts
 
“
di
sa
pp
e
ar
e
d”
,
 
w
hi
ch
 
w
as
 
so
lv
e
d 
by
 
se
tti
n
g 
th
e 
ou
tfl
o
w
 
fro
m
 
ve
ry
 
se
ve
re
 
be
lo
w
 
10
%
 
pr
e
di
ct
e
d 
to
 
ze
ro
.
 
Th
e
 
sa
m
e 
oc
cu
rr
ed
 
in
 
m
ild
 
CO
PD
,
 
w
he
re
 
a
s 
a 
re
su
lt 
of
 
a
n
 
im
pr
o
ve
m
e
n
t i
n
 
lu
n
g 
fu
n
ct
io
n
 
du
e 
to
 
sm
ok
in
g 
ce
ss
at
io
n 
pa
tie
n
ts
 
w
ith
 
a
n
 
FE
V 1
%
 
pr
e
di
ct
e
d 
ar
ou
n
d 
11
0%
 
co
u
ld
 
cr
o
ss
 
th
is
 
lin
e
.
 
Th
e
 
ou
tfl
o
w
 
fro
m
 
m
ild
 
CO
PD
 
a
bo
ve
 
11
0%
 
w
a
s 
al
so
 
se
t t
o
 
ze
ro
.
 
 
 
 
 # 
CO
PD
 
at
tri
bu
ta
bl
e 
m
or
ta
lit
y 
(fix
ed
 
as
 
in
pu
t) w
a
s 
de
fin
ed
 
a
s 
e
xa
ce
rb
a
tio
n
-
re
la
te
d 
m
or
ta
lit
y 
pl
u
s 
ot
he
r 
CO
PD
 
a
ttr
ib
u
ta
bl
e 
m
o
rta
lit
y.
 
Ex
a
ce
rb
a
tio
n
-
re
la
te
d 
m
or
ta
lit
y 
is
 
ca
lc
u
la
te
d 
a
s 
th
e 
ca
se
 
fa
ta
lit
y 
of
 
a
n
 
e
xa
ce
rb
a
tio
n
 
tim
e
s 
th
e 
ex
a
ce
rb
a
tio
n
 
fre
qu
e
n
cy
.
 
If 
th
e 
e
xa
ce
rb
at
io
n 
fre
qu
e
n
cy
 
is
 
re
du
ce
d 
du
rin
g 
th
e 
ca
lcu
la
tio
n
 
of
 
th
e 
ba
se
lin
e 
pa
ra
m
et
e
rs
 
in
 
th
e
 
fir
st
 
ye
a
r,
 
e
xa
ce
rb
at
io
n
-
re
la
te
d 
m
o
rta
lit
y 
is
 
re
du
ce
d,
 
bu
t t
he
 
o
th
er
 
CO
PD
 
a
ttr
ib
u
ta
bl
e 
m
or
ta
lity
 
is
 
in
cr
ea
se
d,
 
su
ch
 
th
at
 
th
e
 
CO
PD
 
a
ttr
ib
u
ta
bl
e 
m
or
ta
lit
y 
an
d 
to
ta
l m
or
ta
lit
y 
di
d 
n
o
t 
ch
an
ge
.
 
In
 
th
e
 
sc
en
a
rio
s 
th
e 
e
xa
ce
rb
at
io
n
 
fre
qu
en
cy
 
w
a
s 
ad
jus
te
d 
af
te
r 
in
iti
al
iza
tio
n
 
of
 
th
e
 
ba
se
lin
e
 
pa
ra
m
e
te
rs
 
a
n
d 
th
er
ef
o
re
 
a 
ch
an
ge
 
in
 
e
xa
ce
rb
a
tio
n
 
fre
qu
en
cy
 
in
 
th
e 
sc
en
ar
io
s 
do
e
s 
ha
ve
 
a
n 
ef
fe
ct
 
o
n 
th
e 
CO
PD
 
at
tri
bu
ta
bl
e
 
m
o
rta
lit
y.
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